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ABSTRACT 
Depression and Alzheimer’s disease (AD) are among the most common clinical diagnosis in older 
people. The relation between depression and AD is complex: depression has been shown to be a risk 
factor, prodromal symptom and a consequence of AD. Increased understanding of the underlying 
mechanisms of depression in AD may lead to early detection and differential diagnosis, and is crucial 
for development of novel and mechanism-based treatments 
The first two studies of this doctoral thesis are exploring the associations between depressive 
symptoms and biomarkers of amyloid deposition and neuronal injury in patients with subjective 
cognitive impairment (SCI), mild cognitive impairment (MCI) and AD. The aims of the third study 
were to describe the use of antidepressants in patients with dementia and to explore the association 
between mortality risk and the use of antidepressants 3 years before the dementia diagnosis.  
CAIDE Dementia Risk Score is taking into account midlife risk and protective factors; age, 
educational level, gender, systolic blood pressure, body mass index, cholesterol level and physical 
activity and APOE genotyping, and can predict dementia over 20 years. The last study was focused 
on exploring the associations between CAIDE Dementia Risk Score and biomarkers of amyloid 
deposition, neuronal injury and small vessel pathology in SCI and MCI patients.  Additionally we 
explored the capacity of CAIDE Dementia Risk Score to predict dementia in a memory clinic 
population. 
Data were obtained from Memory Clinic Karolinska University Hospital Huddinge Sweden (Study I, 
II and IV).  In study III, two large national registries were merged: the Swedish Dementia Registry 
(SveDem) and the Swedish Prescribed Drug Register. 
In study I, analysis of the three different cerebrospinal fluid biomarkers; amyloid beta (CSF Aβ), 
total-tau (CSF t-tau), and phosphorylated-tau did not support the hypothesis that more severe amyloid 
or tau pathologies are associated with more severe depressive symptoms. In contrast, SCI and AD 
patients with depressive symptoms tended to have lower CSF p-tau levels and, in particular, lower 
CSF t-tau levels than those without depression, indicating less severe neuronal injury. In study II, we 
used two different analysis methods of MRI to measure medial temporal lobe atrophy and 
hippocampus volume. Using manual tracing of the hippocampi we found smaller left hippocampus 
volume in SCI patients with depressive symptoms compared to those without depressive symptoms. 
In contrast, AD patients with depressive symptoms had less medial temporal lobe atrophy compared 
with those without depressive symptoms.  
 
In study III, 20,050 patients with incident dementia diagnosed in memory clinics and registered in 
SveDem were included. Information on the total number of medication and all antidepressants 
dispensed at the time of dementia diagnosis and at the first, the second and the third year prior to 
dementia diagnosis was obtained from the Swedish Prescribed Drug Register. During a median follow 
up of 2 years, 5168 (25.8%) dementia patients died. At the time of dementia diagnosis, 5,004 (25.0%) 
patients were on antidepressant treatment. Use of antidepressant treatment for 3 consecutive years 
prior to a dementia diagnosis was associated with a lower mortality risk for all dementia disorders in 
general and particularly in AD. 
 
In study IV, a higher CAIDE Dementia Risk Score was associated with higher CSF t-tau levels, more 
severe medial temporal lobe atrophy and more severe white matter changes. For the CAIDE score 
including APOE, a score above 9 points was associated with lower CSF Aβ, more severe medial 
temporal lobe atrophy and more severe white matter changes. CAIDE Dementia Risk Score (version 
with APOE) performed better at predicting AD compared with CAIDE Dementia Risk Score without 
APOE.  
Conclusion: We found that depressive symptoms in patients with AD and SCI are not associated with 
more amyloid deposition nor more neuronal injury compared with AD and SCI patients without 
depressive symptoms. Thus our results are consistent with the hypothesis that the mechanisms 
underlying depression differ between older people with and without AD. Our results have shown that 
use of antidepressants in prodromal AD stages is associated with a lower mortality risk.  Further 
longitudinal studies are needed to better understand the associations between the use of 
antidepressants and mortality risk in dementia.  
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1 INTRODUCTION 
1.1 ALZHEIMER’S DISEASE   
Major neurocognitive disorder or dementia existed long time before Alois Alzheimer 
described the most common form, Alzheimer’s disease (AD) in 1907 1 . Alzheimer Disease 
International defines the word “dementia” as a general term for progressive degenerative 
syndromes which “affect memory, thinking, behavior and emotions” severely enough to 
interfere with daily life 
2
. 
In Diagnostic and Statistical Manual of Mental Disorders – fifth edition (DSM-5) the term 
“dementia” was replaced with major neurocognitive disorder. The new term emphasizes the 
evolution of the cognitive decline as a continuum from subjective and mild cognitive 
impairment to severe cognitive impairment 
3,4
. It is suggested that the word “dementia” 
expresses a stigmatizing attitude towards older people with cognitive disorders 
4
.  
Stigma associated with major neurocognitive disorder (dementia) has an important impact on 
quality of life, psychological and social well-being 
5
. A higher level of perceived stigma is 
associated with:  more depressive and anxiety symptoms, lower self –esteem, avoidance, 
isolation, reduced social supports and increased dependence 
5
. Health care professionals have 
also been shown to contribute to stigma 
6
. Recent studies report that patients with major 
neurocognitive disorder (dementia) are facing structural discrimination within the health 
service; lack of time for patients and being treated by medical doctors with little experience 
6
. 
Throughout this thesis we will consistently use the term “dementia” as in our studies the 
diagnosis of AD were according to The Manual of the International Statistical Classification 
of Diseases Injuries and Causes of Death 10 (ICD 10), which use the terminology of 
dementia.  
1.1.1 Epidemiology  
Dementia is not a normal part of normal aging, although it is very common in the elderly. In 
2015 the number of people living with dementia worldwide was estimated to 46.8 million
7
 
and there are around 9,9 million new cases each year 
7
. 
AD and vascular dementia are the most common causes of dementia accounting for 50-75% 
and respectively 20-30% of all cases. All other forms account for less than 10-15% of all 
cases
2
. Around 5-7% of individuals younger than 60, are suffering from a form of dementia. 
By age 85 the prevalence increases to more than 50% 
7,8
. 
A large population based study from the UK has shown a significant reduction in the 
 8 
prevalence of dementia during 20 years of follow up
9
, while a study conducted in Spain 
found a reduction of dementia prevalence in men 
10
. The incidence of dementia in a large 
observational study from the Netherlands found no significant reduction in dementia 
occurrence during a 10-year period 
10
, while a study from Sweden suggested that the 
incidence may have decreased during a 20-year period
11
. 
 Causes of dementia: 
Various disorders cause dementia. Mixed forms of dementia often co-exist, as the clinical and 
pathological boundaries between different forms are sometimes indistinct. 
Types of dementia disorders according to ICD 10 dementia in Alzheimer’s disease, mixed 
dementia (vascular and Alzheimer), vascular dementia, dementia in Pick disease, Dementia in 
Creutzfeldt-Jakob disease, Dementia in Huntington’s Disease, Dementia in Parkinson’s 
disease, Dementia in human immunodeficiency virus (HIV) disease, unspecified dementia 
and other dementia (dementia in cerebral lipidosis, epilepsy, hepatolenticular degeneration, 
hypercalcaemia, acquired hypothyroidism, intoxications, Lewy body (disease), multiple 
sclerosis,  neurosyphilis, niacin deficiency [pellagra],  polyarteritis nodosa, systemic lupus 
erythematosus,  trypanosomiasis,  uraemia, vitamin B12 deficiency )
12
. 
1.1.2 Risk factors  
Several risk and protective factors for AD and dementia have been identified. Most of them 
are discussed and presented on http://www.alzrisk.org/.  The greatest risk factor is age
13
. 
Table 1: Most common risk and protective factors for dementia 
                     Risk factors                  Protective factors  
Age   
Genetic  Genetic 
APOE ε 4  
Different genes CR1, PICALM, CLU, 
TREM2, TOMM40) www.alzgene.org 
 
Different genes (APP, APOE ε2)  
www.alzgene.org  
Familial aggregation  
Down Syndrome  
Lifestyle Lifestyle  
Smoking  Physical activity 
High alcohol intake Moderate alcohol intake 
Caffeine
14
 
Diet  Diet 
Saturated fats Mediterranean diet 
Low B vitamins/ high homocysteine  PUFAs and fish related fats 
High sodium intake 
15
 Vitamins B6, B12 and folate 
  9 
Vascular and metabolic  Antioxidant vitamins (A,C, E) 
Cerebrovascular lesions Vitamin D 
Cardiovascular disease Psychosocial factors  
Diabetes mellitus and pre-diabetes High levels of education  
Midlife hypertension High socioeconomic status 
Midlife high BMI (overweight and obesity) High level of complexity of work 
Midlife hypercholesterol Rich social network and social engagement 
Others Mentally stimulating activities 
Depression  Drugs 
Coronary artery bypass surgery Antihypertensive drugs 
Traumatic brain injuries Statins 
Occupational exposure (heavy metals –ELF-
EMFs) 
Hormone replacement therapy 
Infectious agents (herpes simplex virus type 1, 
chlamydophila pneumonia, spirochetes ) 
Non steroid anti-inflammatory drugs  
APP: amyloid precursor protein, APOE: Apolipoprotein E, BMI: Body mass index, CR1: 
complement component receptor, PICALM: phosphatidylinositol binding clathrin assembly 
protein, CLU: clusterin, TOMM40: translocase of outer mitochondrial membrane 40 
homolog, TREM2: triggering receptor expressed on myeloid cells 2, ELF-EMFs: extremely 
low frequency electromagnetic fields, PUFA: polyunsaturated fatty acid. (adapted from 
Solomon et al 
16
) 
1.1.2.1 Genetic risk factors: APOE genotype  
APOE ε4 genotype is the strongest and most studied genetic risk factor for sporadic AD. 
Allele ε4 increases the risk while ε2 has been shown to be protective 17.  Individuals with 
APOE ε4 genotype present an increased vulnerability for other vascular and metabolic risk 
factors like smoking, alcohol, physical inactivity and high intake of saturated fatty acids 
18
.  
APOE ε4 allele increases the risk in an amyloid beta (Aβ) dependent and independent 
manner. Several mechanisms involving amyloid deposition, tau pathology, neuro 
inflammation, lipid metabolism, neurotoxicity, mitochondrial dysfunction have been 
associated with APOE ε4 allele17. APOE ε4 allele increases brain amyloid β burden and 
decreases the amyloid β clearance17,18. 
APOE ε4 carriers are constantly found with increased PET Aβ deposition and lower CSF 
levels of Aβ1-42. It has been reported that APOE ε4 allele carriers present higher 
phosphorylated and total tau levels in cerebrospinal fluid
18,19
, more severe synaptic loss and 
neuroinflammation
17
. A recent study reports that APOE ε4 carriers have increased Aβ 
deposition independently of their cognitive performance (e.g normal cognitive performance 
or with MCI) 
20
. 
 10 
1.1.2.2 Environmental risk factors  
Several modifiable risk factors have been associated with AD: lifestyle, diet, vascular and 
metabolic, depression (table1). 
Several cardiovascular diseases like midlife hypertension, midlife obesity, midlife 
dyslipidemia
21
, diabetes, stroke 
22
, late life heart disease
23
 have been shown to increase the 
risk for AD and dementia.  
 Studies like Cardiovascular Risk Factors Ageing and Dementia (CAIDE), the Framingham 
Heart Study, Honolulu Asia Aging Study (HAAS) have contributed to increased awareness 
on the importance of midlife vascular risk factors for AD and dementia
2
  
1.1.2.3 Risk scores  
There are several risk scores for estimating the risk to develop dementia and research is 
focusing now on validating them in different populations
24
. 
CAIDE Dementia Risk Score is a tool for estimating the risk of dementia in the general 
population. The score has the ability to predict dementia over 20 years (Table 2). There are 
two versions of CAIDE Dementia Risk Score one which takes into account the following 
midlife risk/protective factors:  age, education levels, gender, systolic blood pressure, body 
mass index, cholesterol levels and physical activities and another which include APOE 
genotyping. Total maximum points for the version without APOE is 15 and for the version 
with APOE is 18
21
. However, by adding APOE ε4 allele the score’s capacity to predict 
dementia did not improve in the original population
21
.  
CAIDE Dementia Risk Score was developed in a Finish population and externally validated 
in a population from the USA
25
. Exalto et al.
25
 added to the score other midlife risk factors 
including central obesity, depressed mood, diabetes mellitus, head trauma and smoking. 
Enriching CAIDE Dementia Risk Score with depressed mood the score ‘s capacity to predict 
dementia was not improved 
25
.  
Other risk scores taking into account late life risk factors have included depressive symptoms 
with a good predictive capacity in community-based or primary care settings
24
. Some 
examples include: Australian National University- Alzheimer’s disease Risk Index26, 
Dementia Risk Score in type 2 Diabetes, Brief Dementia Indicator for Primary Care
24
. 
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Table 2: CAIDE Dementia Risk Score in the original publication 
21
 
CAIDE Dementia Risk Score  Version without  
APOE genotype  
Version with  
APOE genotype  
Age <47 years 
47-53 years 
>53 years 
0 
3 
4 
0 
3 
5 
Education ≥10 years 
7-9 years 
0-6 years 
0 
2 
3 
0 
3 
4 
Sex Women 
Men 
0 
1 
0 
1 
SBP ≤140 mmHg 
>140 mmHg 
0 
2 
0 
2 
BMI ≤30 kg/m
2
 
>30 kg/m
2
 
0 
2 
0 
2 
Cholesterol ≤6.5 mmol/l 
>6.5 mmol/l 
0 
2 
0 
1 
Physical activity Active 
Inactive 
0 
1 
0 
1 
APOE ε4 status Non-carrier 
Carrier 
- 
- 
0 
2 
Points, total  Max. 15 Max. 18 
CAIDE: Cardiovascular Risk Factors, Aging and Dementia Study, BMI: body mass index, 
SBP: systolic blood pressure, APOE: apolipoprotein E genotype, (courtesy Dr. Miia 
Kivipelto) 
1.1.3 Neuropathology  
Alois Alzheimer described the major neuropathological features of the disease in 1907: 
amyloid plaques and neurofibrillary tangles in addition to neuronal loss and brain atrophy
1
.  
At a macroscopic examination it can be observed that brains of patients with AD are 
bilaterally symmetrically atrophic with widened sulci, narrowed gyri of all lobes and 
enlargement of the vernicles
27
. A more extensive and severe atrophy can be observed in 
anteromedial regions of frontal and temporal lobe
27
 (Figure 1). 
Anatomically, the medial temporal lobe structures include: the hippocampus, 
parahippocampal cortex, entorhinal cortex, perirhinal cortex
28
. The hippocampus is formed 
by three major units: the dentate fascia, the Ammon’s horn with its 4 subfields Cornu 
Ammonis 1- 4 (CA1 - CA4) and subiculum
27
.  It has complex connectivity with other brain 
regions such as the thalamus, hypothalamus, amygdala, entorhinal cortex, frontal, temporal 
and parietal lobes
29
. The hippocampus play a crucial role in memories processes and it is 
particularly vulnerable in early AD stages
30
.  
 12 
The neuropathological hallmarks of AD- associated pathology are aggregates of abnormal 
proteins. Intraneuronal neurofibrillary tangles consist of hyperphosphorilated tau protein, 
whereas amyloid plaques are extracellular and consist mainly of amyloid beta (Aβ) peptide1 
(Figure 1). These protein accumulations have different predilection for different regions in 
the brain. According to Braak stages neurofibrillary tangles appear first in the allocortex 
(entorhinal cortex and hippocampus)
31, while Aβ accumulates mainly in the isocortex31. The 
spatial and temporal pattern of amyloid deposition is less predictable than that for 
neurofibrillary tangles
32,33
. During the course of the pathological process, both types of 
pathologies spread out systematically throughout the brain, increasing in severity
27
. Earliest 
changes may begin at least 20 years before a clinical diagnosis of AD
34
. 
In the APOE ε4 carriers an accumulation of Aβ plaques is reported18. Microvascular changes 
are common in patients with AD, although they are not considered neuropathological 
hallmarks of AD
31
. 
Figure 1: Characteristic AD type pathology: (A) brain atrophy- magnetic resonance 
imaging (MRI). MRI imaging from a 66-years old healthy control and MRI imaging from 
a 66 years old patient with sporadic Alzheimer’s disease. (B) Bielschowski silver stain 
highlights both plaques (white  arrow) and neurofibrillary tangles (black arrow). 
Magnetic Resonance Images courtesy Dr. Xiaozhen Li, Karolinska University 
Stockholm; Microscopy images courtesy Dr. Nenad Bogdanovic, University Hospital 
Oslo. 
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1.1.4 Diagnosis  
1.1.4.1 Clinical features 
 Cognitive impairment  
Cognitive profiles in patients with subjective cognitive impairment (SCI), mild cognitive 
impairment (MCI) and AD are very heterogeneous
35
. Identifying the affected domains is 
helpful to establish the aetiology and the severity of the cognitive impairment. In patients 
with MCI due to AD the primary neurocognitive feature is decline in memory and learning 
early in the course of the disease; mainly decline in the ability to learn and retain new 
information
36,37
. However impairment in other domains such as executive function, attention, 
language and visuospatial abilities is common in patients with MCI and mild AD
35
.  
Atypical presentations are usually rare; they appear in younger patients (below 65 years of 
age) and other cognitive domains are dominating the clinical picture. 
38
 Posterior cortical 
atrophy (PCA) variant presents with a major impairment in visuospatial (perceptual-motor 
function). A “language” and a “frontal” AD variant have been described with progressive 
aphasia or fontal and behavioural symptoms and relatively preserved memory initially
38,39
. 
DSM 5 recommends assessment of 6 key neurocognitive domains: learning and memory, 
language, perceptual motor function, executive function, complex attention and social 
cognition (Figure 2)
3,4
.  
Figure 2: Neurocognitive domains and subdomains proposed by DSM 5 (adapted from Sachdev et al., 
2014)
4
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  Behavioural impairment 
Behavioural symptoms are non-cognitive symptoms in patients with AD. Several 
neuropsychiatric symptoms such as depression and apathy occur in MCI and mild AD
40,41
. 
Recently, provisional criteria for “mild behavioural impairment” have been recently proposed 
41
. 
The most common behavioural symptoms include: depression/dysphoria, anxiety, apathy, 
sleep disturbance, disinhibited behaviour, verbal and physical aggression, agitation, delusion, 
hallucinations. Behavioural symptoms’ severity is associated with severity of cognitive 
impairment, caregiver burden, increased disability, lower quality of life, earlier 
institutionalization and increased mortality rate
42
. Moreover, behavioural symptoms such as 
psychosis, agitation/ aggression and affective symptoms in incident AD can predict 
progression to more severe AD dementia and death
42
. 
 Functional impairment 
Cognitive and behavioural impairment leads to functional impairment. In patients with SCI 
and MCI the cognitive symptoms do not interfere with instrumental activities of daily living, 
although a functional decline can be observed in patients with MCI
43
.  
The patients’ abilities decline from deterioration in instrumental activities of daily living in 
mild AD to impairment in basic activities of daily living in moderate AD and total 
dependence and institutionalization in severe AD stages
44
. 
Figure 3: Clinical features of Alzheimer’s disease.  ADL: activities of daily living  
  15 
Several scales have been developed to assess the basic and instrumental activities of daily 
living
43
. In patients with AD some of the most used instruments are: Alzheimer’s Disease 
Cooperative Study– Activities of Daily Living (ADCS-ADL) inventory45 the Disability 
Assessment for Dementia (DAD) scale
46
, The Informant Questionnaire on Cognitive 
Decline in the Elderly (IQCODE)
47
. For patients with MCI have been developed new ways 
to assess functional decline; instruments which are assessing speed and accuracy to perform 
activities of daily living or financial capacity
43
.  
1.1.4.2 Diagnostic criteria 
Progression of AD symptomatology occurs on a spectrum from preclinical-asymptomatic 
AD, symptomatic-prodromal AD to clinically manifest AD
48
. Cognitive impairment evolves 
in this time interval from subjective cognitive impairment (SCI), mild cognitive impairment 
(MCI) and dementia (Figure 4). Preclinical AD includes 2 stages an “asymptomatic at-risk 
stage” - individuals without clinical symptoms, but positive biomarkers – and a 
“presymptomatic AD stage” when an individual experience subjective cognitive impairment 
and biomarkers can be positive.  Prodromal AD stage includes mainly patients with MCI 
objectively measured and subjectively observed by a knowledgeable informant or clinician
39
. 
Improved diagnostic techniques and criteria allow a better clinical diagnoses of SCI, MCI and 
AD. However, a diagnosis of definite AD can only be established post-mortem
34
.The 
assessment procedure should take into account different treatable conditions which may 
contribute to cognitive impairment such as depression, hypothyroidism, vitamin deficits and 
alcohol abuse
34
. 
1.1.4.2.1 Subjective cognitive impairment (SCI) 
Individuals with SCI describe a subjective decline in their cognitive function and have normal 
performance on cognitive testing. It is associated with an increased risk for developing 
dementia and several biomarkers of amyloid deposition and neuronal injury can be present at 
this stage
48
. 
 SCI is a heterogeneous clinical entity, being present in different other medical condition or as 
a side effect of treatment and it can be influenced by personal traits 
49,50
. Nowadays there are 
many international efforts to identify SCI due to AD.  Subjective Cognitive Decline Initiative 
(SCD-I) Working group proposed recently research criteria for pre-MCI subjective cognitive 
decline
49
. The criteria requires persistent subjective decline in cognitive functioning and 
 16 
normal cognition at tests used for MCI. The symptoms should not be explained by an acute 
event, MCI, dementia or by another psychiatric and neurologic disease
49
. 
The risk for converting to dementia from SCI has been estimated to 10% in studies with more 
than 4 year follow up; reported conversion rates depend on study design, duration of the 
follow up, and population type (clinic-based or general population)
51,52
. The annual 
conversion rate from SCI to MCI is estimated to 6.6% and from SCI to dementia is 2.3% 
51
.  
A recent meta-analysis found that patients with SCI had a similar prevalence of PET 
amyloid burden as cognitively normal subjects, suggesting that SCI may not have an 
increased risk for AD than cognitively normal individuals
53
.  Obviously, future research 
focusing on associations between SCI and biomarkers of amyloid deposition and neuronal 
injury are needed. 
1.1.4.2.2 Mild Cognitive Impairment (MCI) 
MCI criteria have gone through several revisions after the introduction of the concept by 
Mayo Clinic group 
54
. Most used criteria are: 
 Mayo Clinic MCI criteria proposed originally by Petersen et al. in 199954, are able to 
diagnose mainly patients with amnestic MCI. These criteria require a cognitive 
decline from a previous performance level in memory and learning domain 
objectively measured, subjective cognitive impairment, preserved general cognitive 
function, preserved independence in performing activities of daily living and no 
dementia disorder 
55
. 
 International Working Group (IWG) criteria 56 are a broad conceptualization of the 
Mayo Clinic criteria. It require cognitive decline from a previous performance level in 
one or several cognitive domains objectively measured, subjective cognitive 
impairment, preserved independence in activities of daily living, no dementia 
disorder. The International Working Group   criteria are used throughout this thesis. 
 DSM5 criteria for mild neurocognitive disease are relatively similar with the 
International Working Group criteria for MCI. In addition it requires that the 
cognitive impairment does not occur in the context of delirium or another mental 
disorder as for example major depression 
3,4
   
 National Institute on Aging-Alzheimer’s Association (NIA-AA) 36 clinical criteria are 
similar with the International Working Group criteria. NIA-AA research criteria for 
MCI due to AD, proposed use of biomarkers of amyloid deposition or/and neuronal 
injury to diagnose MCI due to AD 
36
. Patients with MCI due to AD intermediate 
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likelihood fulfil clinical criteria of MCI and present at least one positive biomarker for 
amyloid deposition or neuronal injury. MCI due to AD high likelihood is diagnosed 
when both biomarkers for amyloid deposition and neuronal injury are positive. MCI 
unlikely due to AD is considered when none of the biomarkers are positive.  
Recently, the prevalence of MCI diagnosed according with the DSM-5 criteria was half than 
using Petersen criteria 
57
. One of the explanation is that patients with MCI associated with 
other mental disorders as major depression for example do not fulfil the DSM-5 criteria
57
.  
The risk for conversion from MCI to dementia has been estimated to 30-40% and annual 
conversion rates have varied between 5-10% depending on study design, duration of the 
follow up, and population type  (clinic-based or general population) 
52,58
Similarly the risk for 
conversion from MCI to AD has been estimated to 30% with annual conversion rates of 7% 
depending on study design
58
.  
1.1.4.2.3 Dementia in Alzheimer’s disease  
According with ICD 10 a diagnosis of dementia requires decline in both memory (typically 
registration, storage and retrieval of new information) and thinking that leads to deterioration 
from previous level of daily life functioning. Symptoms duration should have been evident 
for at least 6 months. A diagnosis of dementia in AD according to ICD 10 criteria requires 
presence of dementia, insidious deterioration which interferes with activities of daily living 
and do not occur in the context of other brain disease that can induce dementia or of a sudden 
onset or of neurological symptoms of focal damage
12
.  
The DSM 5 criteria for major neurocognitive disorder require a significant cognitive decline 
from a previous performance level in one or several cognitive domains measured objectively 
by the neuropsychological tests and reported subjectively. The cognitive impairment 
interferes with instrumental activity of daily living and do not occur in the context of delirium 
or others mental disorders. Major cognitive impairment can be with or without behavioural 
impairment 
3,4
.  
There are no studies to compare those two concepts “dementia” and “major neurocognitive 
disorder”.  It has been suggest that the concept of¨ “ major neurocognitive disorder” may be 
broader than concept of “dementia”. A diagnosis of “dementia” requires memory impairment 
while a diagnosis of “major neurocognitive disorder” is more flexible and requires 
impairment in any neurocognitive domain. DSM 5 recommendations for clinicians are to 
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establish first a diagnosis of neurocognitive disorder and later on the severity of the disorder: 
minor or major 
3,4
.  
The diagnosis of AD is made based on the NIA-AA criteria
37
 according to which the 
diagnosed is classified as: 
1. Probable AD (typical clinical presentation) 
2. Probable AD with an increased level of certainty (patients with documented cognitive 
decline over time, patients with an autosomal genetic mutation for AD) 
3. Probable AD with positive biomarkers of amyloid deposition or /and neuronal injury 
4. Possible AD (atypical clinical presentation or etiologically mixed presentation ) 
5.  Possible AD with positive biomarkers of amyloid deposition or/and neuronal injury   
 
1.1.4.3 Biomarkers   
A biological marker or a  “biomarker” is defined by National Institutes of Health (NIH)- 
Biomarkers definition working group as “ a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention”59. 
Most of the current biomarkers for AD are diagnostic biomarkers; are used to increase 
diagnostic accuracy and for risk assessment in prodromal stages of AD. In clinical practice 
Figure 4: Cognitive decline in different stages of AD: preclinical AD, prodromal AD 
and AD-dementia. Presence of SCI may indicate late stage of preclinical AD. MCI 
and dementia present objective cognitive impairment. Not all patients with SCI and 
MCI develop AD-dementia, many of them will evolve towards normal aging. AD: 
Alzheimer’s disease, SCI: subjective cognitive impairment, MCI: mild cognitive 
impairment. (adapted from Jessen et al 2014)  
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none of the current biomarkers are used for staging AD, measuring progression of AD or 
predicting response to treatment 
60
. 
A good diagnostic biomarker should be able to 
39,61
. 
 Detect AD pathology 
 Be validated in post-mortem confirmed AD cases 
 Is present in all stages of AD 
 Detect early pathological changes of AD  (even in asymptomatic stages) 
 Distinguish AD pathological changes from other pathologies involved in other 
dementia disorders 
 Be reliable 
 Be non-invasive 
 Be easy to perform 
 Be economically affordable  
1.1.4.3.1 Markers of amyloid deposition: 
 Cerebrospinal fluid- amyloid beta (CSF Aβ)    
 Different Aβ isoforms such as Aβ 40 and Aβ 42 can be measured in the cerebrospinal fluid 
(CSF). CSF Aβ42 levels and Aβ 42:Aβ40 ratio are decreased in patients with AD62. Post 
mortem studies have shown that lower levels of CSF Aβ correlate with cortical amyloid β 
plaques and can distinguish between AD and healthy controls and AD and other dementia 
diagnosis
63
. The CSF levels of Aβ42 are decreasing relatively early in the course of the 
disease
64
. Recently, CSF Aβ42 levels have been found to decrease slowly in some cognitively 
normal middle aged people, and this pattern was more accentuated in APOE4 ε4 carriers65. It 
is considered a reliable biomarker. However, a large variability in the results obtained with 
the same method across different laboratories has been reported. Several cut-offs have been 
proposed for CSF-Aβ4266. It is a relatively invasive procedure as a lumbar puncture is 
required to collect CSF, but it is among the cheapest diagnostic biomarkers of AD and it is 
used in specialized units.  
 Amyloid -Positron emission tomography (Amyloid-PET) 
Pittsburgh compound B (PiB) was the first PET tracer used to measure fibrillary amyloid in 
vivo and since then different other PET-tracers have been developed 
62
. Detection of amyloid 
with PET was validated with neuropathologically confirmed cases of AD. A higher uptake of 
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amyloid tracer on PET scans correlates with lower CSF Aβ1-42 
67
.  Amyloid PET is a reliable 
method and can detect early AD changes. In preclinical stages of AD prevalence of amyloid 
positive on PET scans is associated with age and APOE ε4 status53. It is useful for differential 
diagnosis of early onset dementia 
68
. An intravenous injection is needed to deliver the 
radioactive substance. The patient is exposed to a higher amount of radiation when a 
computer tomography (CT) scan is performed comparing to a magnetic resonance imaging 
(MRI) scan. The high costs makes PET mainly used for research purposes. 
62
 
1.1.4.3.2 Markers of neuronal injury: 
 Cerebrospinal fluid- total tau (CSF t-tau) and phosphorylated tau (CSF p-tau) 
CSF t-tau and p-tau are relatively a reliable measures of tau pathology. Increased CSF t-tau 
and p-tau have been observed in patients with AD and are correlated with neurofibrillary 
tangles in post-mortem studies of confirmed AD cases
69
. A large variability and several cut-
off points have been proposed by different laboratories using same measuring techniques
66
. 
CSF t-tau levels are not specific for AD as it increases in different other neurodegenerative 
disease
70
, however the addition of p-tau levels increased the specificity for the disease
71
. 
Some studies suggested that CSF tau correlates with cognitive progression
60
. 
 Hippocampal atrophy or medial temporal lobe atrophy 
Hippocampal atrophy and medial temporal lobe atrophy on structural MRI scans correlates 
with tau pathology
72
 and cognitive impairment
60
. Hippocampal atrophy can distinguish with a 
good accuracy between patients with AD and healthy controls and is used in risk assessment 
in patients with MCI and SCI
73
. In population based studies hippocampal volume decrease 
gradually from the age of 30-40 until 60 years when the shrinkage becomes more severe
74,75
. 
Hippocampal atrophy can occur in other dementia, while patients with atypical AD 
presentations can depict parietal or frontal lobe atrophy mainly with no involvement of the 
hippocampus
38
. Hippocampus region present relatively small anatomical variability 
compared with other cortical regions and several methods have been developed to measure 
it
76
. Manual delineation of hippocampal volume is a method with high accuracy, but it is time 
consuming and mainly used for research purposes. Visual assessment of the medial temporal 
lobe atrophy is a method used in clinical practice, but it is less accurate for detecting subtle 
variation
77
. Visual assessment correlates well with the manual delineation of the hippocampal 
volume
78
 and can predict conversion to AD in patients with MCI
77,79
. Automated methods are 
now developed and have potential to be used in clinical practice
80
. Hippocampal and medial 
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temporal lobe atrophy measured on MRI are non-invasive and relatively inexpensive 
biomarkers
76
.  
Apart from hippocampus, other brain regions are atrophied in patients with AD. An index of 
AD-like patterns of atrophy based on structural MRI have been shown to predict conversion 
from MCI to AD
81
. 
 Tau Positron Emision tomography (Tau-PET) 
Different tracers for tau are underdevelopment and used for research proposes. Imaging tau in 
vivo will facilitate research into underlying mechanism in AD
70
. 
1.1.4.3.3 White matter lesions (WML) or white matter changes (WMC) 
WML are attributed to small vessel chronic ischemia
82
 and affects executive function 
(planning, organizing)
82
. Prevalence of WML in population-based studies varies between 45-
95%
83
.  WML are common in prodromal stages of AD and more severe parietal WML can 
predict conversion to AD in patients with hippocampal atrophy or pathological CSF levels of 
t-tau
84,85
. WML are very common in patients with AD and prevalence is higher in vascular 
dementia
86
 . A recent study have shown that alterations in white matter integrity measured 
with diffusion tensor MRI (DTI-MRI) precede gray matter atrophy in patients with MCI and 
pathological CSF Aβ levels87.  
1.1.4.3.4 Interaction between the biomarkers  
Understanding the particular sequence and evolution in time of biomarkers abnormalities is 
essential in staging the disease in presymptomatic stages and evaluating the patient state and 
disease prognosis 
88
. Several models that estimate biomarker dynamics have been proposed, 
most of them assume a single progression pattern. The first model proposed by Jack et al. in 
2010 suggest that markers of amyloid deposition (CSF Aβ and Amyloid PET) occur first, 
followed by biomarkers of neuronal injury (
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F-fluordeoxyglucose PET (FDG-PET), CSF t-
tau, CSF p-tau and hippocampal atrophy) and later on clinical symptoms as cognitive 
impairment, neuropsychiatric symptoms and functional impairment appear
60
. 
More recently, hypothetical model of dynamic biomarkers proposed by Jack et al. in 2013 
suggests that amyloid and tau pathology can begin independently one from another and both 
pathologies are necessary but not sufficient to produce clinical symptoms of AD
88
. Other 
pathologies like small vessel disease, inflammation, Lewy bodies, TDP-43 inclusions
69
,  
genetic factors and brain cognitive reserve may also play a role.   
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1.1.5 Treatment of Alzheimer’s disease 
The approved treatment for AD is symptomatic. Acetylcholinesterase inhibitors (AChEI) as 
donepezil, rivastigmine and galantamine inhibit acetylcholinesterase and enhance 
acetylcholine in the synaptic cleft. Apart from AChEI memantine is licensed for moderate to 
severe AD, it is a partial antagonist of N-Methyl-D-aspartic acid (NMDA) -receptor
34
.  
No disease modifying therapy is approved for clinical use. Many trials targeting Aβ plaques 
in patients with early or moderate AD have been more or less unsuccessful
89
.However, new 
promising Aβ antibodies are in early phase trials89. One of the possible explanations for the 
unsuccessful trials was that the intervention was too late in the course of the AD. Secondary 
prevention trials are on going to intervene with disease modifying drugs in asymptomatic 
individuals with pathological biomarkers. One of these trials is the A4 trial (Anti-Amyloid 
Treatment in Asymptomatic Alzheimer’s Disease); it will test the hypothesis that decreasing 
amyloid burden will prevent or slow the occurrence of the clinical symptoms of AD 
90
.   
Recent studies have shown that life style interventions could improve or maintain cognitive 
functioning in individuals at risk to develop dementia 
91,92
 
The treatment of choice for the behavioural and psychological symptoms in AD is non 
pharmacological; psychological treatment, music therapy, aromatherapy, physical exercise 
are useful in treating agitation/aggression and depressive symptoms
93,94
. Medication should 
be reserved for extreme cases. Atypical antipsychotics as risperidone, olanzapine and 
aripiprazole show modest benefits for treating psychotic symptoms, aggression or agitation in 
patients with AD for a short period of time (12 weeks). Antipsychotics have severe side 
effects as sedation, gait disturbance, prolonged QTc, thromboembolic, cerebrovascular events 
and increased mortality 
94,95
 . A recent trial suggest that atypical antipsychotics can have a 
modest benefit on psychotic symptom for long term use (more than 24 weeks)
96
. 
Use of antidepressant treatment for treatment of depressive symptoms will be discussed late 
on in the thesis (treatment of depression in AD). It has been suggested that citalopram may 
reduce agitation/aggression
94
.  
1.1.6 Life expectancy with Alzheimer’s disease  
AD has a long asymptomatic stage and can go under diagnosed for several years. The average 
length of time between the occurrence of the mild cognitive impairment and diagnosis of AD 
is estimated to 3 years
97
. Life expectancy in patients with AD varies largely, the average life 
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expectancy after diagnosis is 7 to 10 years
98
 but it can varies between 3 years or up to 20 
years depending on study design , age of the studied population 
99,100
. 
1.1.6.1 Factors associated with increased mortality risk in AD  
Life expectancy after a diagnosis of AD depends on numerous factors and their complex 
interactions. Several of them have been identified: 
 Age at onset is the main predictor of the life expectancy, older people having a higher 
mortality rate
100
 
 Male Gender has higher mortality rates after the initial AD diagnosis101 
 Severity of the cognitive impairment at diagnosis101 
 Behavioural symptoms at the time of AD diagnosis was associated with increased 
mortality rate
102
. 
 Comorbidities:  
In the elderly population over 67 years of age life expectancy decrease with each additional 
chronic condition
103
. Patients with AD and cardiovascular disease, diabetes, genitourinary 
diseases and chronic obstructive pulmonary disease have a shorter life span than AD patients 
without these comorbidities
104,105
.  
 Medication:  
Intake of a high number of medications reflects a high number of chronic comorbidities and 
is associated with a higher mortality risk
101
. Use of cholinesterase inhibitors in patients with 
AD can reduce the mortality risk and slow the disease progression
106
.  
Psychotropic medication is often used in the elderly with AD. Use of antipsychotic 
medication has been associated with increased mortality risk in elderly with AD and 
dementia
95,107
.   
The evidence however is conflicting regarding use of antidepressant medication and 
mortality rate.  Recently, a large retrospective case-control study reported a small but 
increased mortality risk in patients with AD or dementia using antidepressants 
95
. 
Meanwhile, studies conducted in nursing homes have reported decreased mortality rates in 
patients using antidepressants with an increased protective effect in those who used 
antidepressant treatment more than one year
108,109
. Moreover, effective treatment of 
behavioural symptoms in AD with antidepressants was associated with lower mortality rate 
in nursing home patients with AD and other forms of dementia
109
.  
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1.2 LATE LIFE DEPRESSION  
Depression is an important cause of years lived with disabilities worldwide
110
. It is also the 
leading cause of disease burden for women
111
. Depression and depressive symptoms are 
often under-diagnosed in older people 
112
. 
1.2.1 Epidemiology 
Depression is a common condition throughout the life span, with important clinical 
consequences such as functional impairment, reduced quality of life, and increased mortality 
113
. The prevalence and incidence varies largely across studies depending on study design, 
criteria used to assess depression and settings.  Lifetime prevalence of major depressive 
disorder varies between 3% in Japan and 16.9 % in the USA, with the majority of countries 
reporting a range between 8% to 12%
114
. The gender ratio shows a lifetime prevalence 
estimated at 20.4% in women and 9.6% in men
115
.  
The overall prevalence of depressive disorders in older adults varies between 10-20% 
116
. In 
elderly population the prevalence of major depressive disorder decreases with age 
115
 , while 
the prevalence of depressive symptoms increases with age 
117
. Prevalence of major 
depressive disorder varies between settings: 1-6.3% in the community, 4-10% in primary 
care units, 15-30 % in clinical in-patient units and 6-24% in long term care units 
113
 
In older adults prevalence of minor depressive disorder varies between settings: 1.4-23% in 
the community, 5-20% in primary care units, 10-30 % in clinical in-patient units and 10-
30% in long term care units 
113,118
. Patients with minor depression have an increased risk to 
develop dementia 
113
. 
1.2.2 Diagnosis  
1.2.2.1 Depressive symptoms in late life  
Late life depression (over 60 years) is considered to have a more chronic course with a higher 
relapse rate compared with depression in younger patients 
119
. Depression in late life is 
associated with female gender, low socio-economic status, reduced social support and an 
increased sense of loneliness, recent adverse life events (e.g. bereavement) and coexisting 
medical illnesses
112
.  
Depression is very frequent among older people with associated comorbidities, like AD, 
Parkinson disease, stroke, diabetes 
120,121
. Co-occurrence of depression and another medical 
illnesses is strongly associated with poor self-management, substance abuse, poor adherence 
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to treatment
122
, increased use of health services with early institutionalization and increased 
mortality
123
.  
The clinical presentation of depression in older people has some particularities when 
compared to depression in younger people
124
.  In a meta-analysis of 11 studies, patients 
suffering from late life depression were found to have more psychomotor agitation, somatic 
symptoms and hypochondriasis, less guilt and less sexual interest 
124
. 
The core symptom, depressed mood, may be less common in late life depression compared 
with depression early in life
120
. More unspecific symptoms such as anxiety, social 
withdrawal, psychomotor agitation, irritability, sleeping problems, pain and somatic 
symptoms may be more common in late life depression than in younger patients with 
depression
119,124
.  
Psychotic symptoms as delusional ideation regarding poverty, physical illness or with 
nihilistic content are common in late life depression 
125
. Recognition of depression in older 
people is a priority as elderly suffering from depression have a higher suicide risk
126
. 
However, recognition of depression in older adults may be difficult due to increased tendency 
to alexithymia and somatisation
127
, which sometimes could dominate the clinical picture
112
. 
1.2.2.2 Cognitive impairment in late life depression  
Cognitive profile in late life depression is very heterogeneous
128
. Decline in executive 
function is common in both acute and euthymic states and it can be associated with 
difficulties in verbal and non-verbal learning and recall. Retention, recognition memory, 
implicit learning and language fluency are relatively intact in late life depression
128
. 
Difficulties in recall tasks support the implication of frontostriatal pathways in late life 
depression
129
. These cognitive symptoms may be reversible during successful antidepressant 
treatment. In some cases, symptoms may persist and even progress to dementia.  
Patients with depression in AD have a more severe impairment in several cognitive domains 
such as complex attention, executive function, verbal fluency and memory 
130,131
. In patients 
with dementia, depression may aggravates the rates of cognitive decline
132
. 
1.2.2.3 Diagnostic criteria  
Diagnosis of depression is purely clinical, as no diagnostic biomarker for depression has been 
approved for clinical practice. National Institute of Mental Health has launched the Research 
Domain Criteria project (RDoC) to “create a framework for research on pathophysiology 
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especially for genomics and neuroscience, which ultimately will inform future classification 
schemes”133,134. 
DSM-5 criteria for major depressive disorder require the presence of a minimum 5 symptoms 
(at least one core symptom) over a 2-week period. Core symptoms are depressive mood or 
anhedonia. Additional symptoms are: increased or decreased appetite, clinically significant 
weight gain or loss, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, 
loss of energy, loss of concentration, difficulties in taking decisions, feelings of worthlessness 
or excessive or inappropriate guilt, and suicidal ideation
112,125,135
. DSM 5 introduced the 
concept of depression without sadness acknowledging that elderly complain more of loss of 
motivation, lack of energy, withdrawal and physical complains. Therefore DSM5 criteria are 
more likely to identify depression in older people compared to previous DSM criteria for 
major depressive disorder 
125
. 
ICD criteria are frequently used in Europe and those criteria for depressive disorders are 
mainly similar to DSM criteria
12
. 
Sub-threshold depression or subsyndromal symptomatic depression refers to clinically 
symptoms of major depression without fulfilling all criteria that leads to reduction in social 
function. Several criteria have been proposed for sub-threshold depression in younger 
patients
136
 and in older people
137,138
. Lyness et al. 2007 showed that there are many 
similarities among the criteria
138
. Judd et al. criteria require more than 2 depressive symptoms 
at a threshold level and one of the symptoms is either anhedonia or depressive mood
136
. 
Lyness et al. require more than 2 depressive symptoms at a threshold or sub-threshold level, 
when one of the symptoms is either anhedonia or depressive mood 
138
.  For both criteria 
depressive symptoms should be for more than 2 weeks
136,138
 . Several studies defined sub-
threshold depression as scoring above an established cut-off point on depression rating scale 
(e.g. Hamilton rating scale for depression (HAM-D) ≥ 10 138 or Geriatric Depression scale 
(GDS) ≥12137). 
Depressive symptoms are included as diagnostic criteria for several affective disorders (see 
list below of several DSM 5 diagnoses). In clinical practice it is important for the patient to 
get an accurate diagnosis and appropriate treatment.
135
 
125
 
 Major Depressive Disorder 
 Persistent Depressive Disorder which replace the dysthymic disorder from DSM IV 
 Disruptive Mood Dysregulation Disorder 
 Premenstrual Dysphonic Disorder 
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 Substance/Medication-Induced Depressive Disorder 
Depressive Disorder Due to Another Medical Condition (following stroke, with 
Huntington’s disease, with Parkinson Disease, hypothyroidism) 
 Other Specified Depressive Disorder (recurrent brief depression, short-duration 
depressive episode: 4-13 days, depressive episode with insufficient symptoms) 
 Bipolar Affective Disorder  
 Cyclothymic Disorder 
 Unspecified Depressive Disorder 
 Complicated bereavement have been excluded from DSM 5, but is often used in 
clinical practice  
1.2.3 Relationship between depression and Alzheimer’s disease 
The relation between depression and cognitive impairment is complex; major depression in 
late-life is often accompanied by cognitive impairment. Additionally, depression has been 
shown to be a risk factor, a prodromal symptom and a consequence of AD 
139
 
121
. 
 Depression as a risk factor for AD 
Epidemiological studies suggest that depression/ depressive symptoms are a risk factor for 
AD. The evidence however is inconclusive regarding the risk associated with early-life 
depression (before 60 years of age) and late-life depression (after 60 years of age). Studies 
with long follow up periods report that patients with recurrent depression earlier in life have a 
high risk for AD 
140–143
 . Other studies did not find this association despite relatively long 
follow up periods
144,145
.  
The majority of epidemiological studies reports late life depression as a risk factor for AD
146
 
144
. However, the several studies designed in clinical settings found no association between 
depression in patients with MCI and risk of progression to AD
147,148
.  These studies suggest 
that late life depression is an early symptom of AD rather than a risk factor 
144
.  
 Depression as a prodromal symptom of Alzheimer’s disease 
Differentiating between depression as a behavioural symptom of AD and depression with 
cognitive impairment is challenging in clinical practice. Depression is very common in 
prodromal stages of AD
117
 and in the same time it is a treatable cause of subjective or mild 
cognitive impairment
149
.  
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Amyloid deposition and tau pathology occur at least 20 years before the occurrence of 
clinical symptoms of AD
88
 . Therefore depression (late life or late onset depression) in 
preclinical or prodromal stages of AD can be considered as an early behavioural symptom of 
AD. Depression or depressive symptoms coexist with cognitive impairment in patients with 
prodromal AD (10 -20% of cases of AD are preceded by depression
121
) and are associated 
with increased risk of progression to AD
150
.  
However, studies in cognitively normal individuals have shown that depressive symptoms do 
not differ between patients who developed subsequent cognitive impairment and those who 
remain cognitively normal
117
. 
 Depression in Alzheimer’s disease  
The prevalence of depression in AD varies across studies
121
. Around 20-30% patients with 
AD suffer from depression or sub-threshold depression
121
. Population based studies report a 
prevalence of depression/depressive symptoms between 5% and 35%
151
. Clinic-based studies 
report relatively similar frequencies when depressive symptoms are measured
152
, while the 
frequencies are much lower (0.9%-4.8%) when more strict criteria for major depression were 
used
153
. Few studies have reported on incidence of depression in AD, but an incidence of 2% 
per year has been reported for major depressive disorder
153
.  
A major depressive episode in AD usually includes less severe symptoms and its duration is 
usually shorter than major depressive episode in younger patients. Symptoms such as 
dysphoria, anhedonia, social isolation or irritability are most common in depression in AD 
154
. Prevalence and incidence of depression increase in early stages and decrease in late stages 
of AD
155,156
. Decline in cognitive performance including language abilities can make 
depression difficult to assess in late stages of AD
157
. However, studies conducted in nursing 
homes reported a relatively high prevalence (21.2%), incidence (15%) and persistence (45%) 
of depressive symptoms in dementia 
158
.  
Younger age, increased number of comorbidities, bereavement, greater impairment in 
activities of daily living and previous depression have been associated with an increased risk 
for occurrence and persistence of depression in AD 
152,159
. The evidence remains inconclusive 
regarding the association between severity of depression and severity of cognitive impairment 
160
. However, in a longitudinal study major depression was found to accelerate the cognitive 
decline in AD and dementia 
132
. Mood symptoms defined as depression, anxiety and apathy 
measured with neuropsychiatric inventory have been associated with increased severity of 
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impairment in executive function, visual memory and working memory in patients with 
AD
161
. 
1.2.4 Mechanisms of depression in Alzheimer’s disease  
The mechanisms underlying depression in older people are only partially known, and are 
likely heterogeneous, involving a number of different pathophysiological changes, several of 
which are shared with AD.  
 Genetics  
Several genetic factors have been associated with late life depression and neuropsychiatric 
symptoms in AD. APOE ε4 allele is a risk factor for AD and a recent study reported an 
association between APOE ε4 allele and late life depression162. Prevalence of APOE ε4 allele 
is higher in AD patients with depressive symptoms compared with AD patients without 
depressive symptoms
163
. APOE ε4 allele and depressive symptoms in cognitively normal, 
SCI and MCI individuals are strongly associated with conversion to AD or dementia
164,165
. 
Serotonin system is affected in both AD and depression
166
. Some studies found associations 
between polymorphisms in serotonin transporter gene (SLC6A4) and serotonin receptor 2A 
gene (HTR2A) and depressive symptoms in AD patients 
167
, while other studies did not found 
such associations
168
. Response to selective serotonin reuptake inhibitors (SSRI) in patients 
with late life depression is influenced by polymorphism in serotonin 1B (HTR1B) and 1A 
(HTR1A) receptor genes
169
.  
Symptoms of anhedonia in major depression 
170
 and apathy in AD have been associated with 
deregulation in dopamine system
171
. A study from the UK found that higher scores on NPI 
depression and anxiety items were associated with dopamine receptor D4 (DRD4) 2R 
allele
172
. The role of genes related to other systems of neurotransmitters with potential 
relevance for depression in AD needs to be evaluated.  
Finally, the brain derived neurotrophic factor (BDNF) Val66Met polymorphism may increase 
susceptibility for depression in AD
173
.  
 Cerebrovascular mechanisms: “vascular depression” hypothesis  
The link between late life depression and cerebrovascular disease is well established. 
“Vascular depression”174 describes a subtype of late life depression175 where 
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“cerebrovascular disease may predispose, precipitate or perpetuate some geriatric 
depressive syndromes”176.   
Patients with depression and cerebrovascular disease often have ischemic lesions and small 
regions of hypoperfusion leading to disruption of the frontolimbic and frontostriatal circuits 
174
. Periventricular and frontal white matter hyperintensities on MRI reflect small vessel 
pathology
86
. These vascular lesions are associated with higher score for depression in 
patients with late life depression 
177
 and depression in AD 
178
. 
 Hypothalamic-pituitary-adrenal (HPA) axis and hippocampal atrophy  
 Corticotrophin release factor, in chronic depression and AD, activates the hypothalamic-
pituitary-adrenal (HPA) axis and increases release of stress hormones including 
glucocorticoids.   
Hippocampus, cornu ammonis 1- 3 (CA1-CA3) subfields and subiculum in particular are 
very sensitive to increased cortisol levels, reduced levels of serotonin and BDNF occurring in 
depression and AD
29,179
. Hippocampal atrophy, accordingly, is commonly found in AD and 
depression.  
The association between late life depression and reduced hippocampal volume is conflicting 
as several cross-sectional and longitudinal studies report such an association
180,181
, while no 
other studies do 
180,182
. Some studies suggest that hippocampal atrophy is a temporary state in 
the evolution of depression since no significant difference could be observed between 
patients with depression in remission and healthy controls
183
. Hippocampal atrophy in late 
life depression is associated with poor response to antidepressant treatment
184
 and can be 
considered a predictive marker of response to treatment
184
.  
Increased levels of glucocorticoids promote Aβ formation139,185 and suppress hippocampal 
neurogenesis 
186
 in patients with late life depression and AD 
185
. 
However, there is inconclusive evidence supporting the major role of HPA axis activation in 
late life depression 
177
 and in  depression in AD
139,185
. In a recent study increased cortisol 
levels in cerebrospinal fluid (CSF) were associated with cognitive impairment in MCI due to 
AD and in AD patients, but no significant associations were found with depression scores
187
. 
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 Amyloid β plaques formation and neurodegenerative processes 
Processes of abnormal protein accumulation in AD lead to neurobiological changes that can 
impair networks implicated in depression
188
. Therefore patients with depression in AD have a 
poor response to classical antidepressant treatment
189
. 
Studies using biomarkers of Aβ deposition and neuronal injury and studies of neuropathology 
have tried to explain the underlying mechanisms in late life depression and depression in AD.   
 PET: Several studies using PET to visualize Aβ plaques in vivo suggest an 
association between increased amyloid deposition and late life depression
190–193
 while 
other studies did not find such association
194,195
. Moreover depressive symptoms in 
patients with MCI and PET Aβ positive are associated with higher amyloid load 
compared with non depressed Aβ positive MCI patients196. 
 CSF: Several studies suggest an association between lower CSF Aβ1-42 levels and late 
life depression
197
, while others found increased levels or no significant association 
between CSF Aβ1-42 levels and late life depression
198–200
. In patients with AD and 
depressive symptoms Aβ1-42 was found not significantly different than in patients with 
AD and without depression
200,201
. 
Most of the studies reported no associations between CSF t-tau or p-tau and late life 
depression
188,202
 and depression in AD
201
.  
 Structural MRI: MRI studies have shown associations between late life depression 
and brain atrophy. Hippocampal
180
, entorhinal cortex
203
 and orbitofrontal cortex 
atrophy have been consistently reported in late life depression
180
. Depressive 
symptoms in AD patients are associated with cortical thinning in temporal and 
parietal regions
204,205
 compared with AD patients without depressive symptoms. 
Moreover, more severe cortical thinning have been associated with higher CSF t-tau 
levels in AD patients with depressed symptoms
204
. 
 Neuropathology: Studies on postmortem patients’ brains with late life depression 
failed to show an association between depressive symptoms and amyloid plaques and 
neurofibrillary tangles
206
. Meanwhile patients with AD and depressive symptoms 
present more amyloid plaques and neurofibrilary tangles than AD patients without 
depressive symptoms
207,208
.  
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 Neuroinflammatory changes  
Chronic inflammation has been implicated in both depression
209
 and AD
210
. Some researchers 
propose that activation of inflammatory pathways in late life depression increase vulnerability 
for vascular events and amyloid accumulation
211
. 
Few studies addressed the role of inflammation in AD depression. In recent studies lower 
levels of anti inflammatory interleukin 10 in the CSF
212
 and raised serum levels of pro 
inflammatory tumor necrosis factor were associated with depressive symptoms in AD
213
.  
Figure 5: Potential mechanism involved in depression that can increase the risk for AD 
Chronic depression (with severe recurrent depressive episodes) is associated with 
hyperactivity of hypothalamic-pituitray axis which leads to increased secretion of stress 
hormones like glucocorticoids contributing to the pro-inflammatory environment, 
hippocampal atrophy, increased levels of amyloid plaques and alteration in growth factors 
(brain-derived neurotrophic factor). Proinfalmmatory processes increase brain vulnerability 
for cerebrovascular disease particulary in middle age individuals; ischemic leasions have 
been involved in dysruption of the frontolimbic and frontostriatal connectivity. Presence of 
the ischemic lesions and hypoperfusion processes in late life depression are associated with 
a poor respons to antidepressant treatment and increase the number of recurrent depressive 
episodes. All these processes increase the risk for brain aging and development of cognitive 
impairment, Alzheimer’s disease.  
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 Nerve growth factors  
Decreased levels of BDNF have been involved in late life depression and AD. BDNF has an 
important role in maintaining the integrity of the hippocampus 
214
. A recent study, has shown 
that patients with late life depression and MCI have lower CSF- BDNF levels compared with 
MCI patients without depression
215
 . The role of BDNF and other nerve growth factors in 
depression in AD needs to be further explored. 
1.2.5 Assessment of depression in Alzheimer’s disease   
Several scales are used to screen for depressive symptoms or to measure severity of 
depressive symptoms in older people with and without AD. None of the following scales is 
a diagnostic tool for depression in AD. Some examples of the most commonly used scales for 
clinical and research purposes: 
 Cornell Scale for Depression in Dementia (CSDD):  
The scale was developed initially to screen for depressive symptoms among elderly with 
dementia 
216
, but it can be applied in elderly without dementia 
217
. It consists of two semi-
structured interviews where both patient and caregiver are interviewed. It takes around 25 
minutes to administer the scale. 
The scale shows a good reliability, sensitivity and validity for measuring depressive 
symptoms in older people with AD
216
 from hospital
218
 and nursing homes
159
. The scale is 
widely used. Other versions have been translated from English, culturally adapted and 
validated
219
. 
The scale has 19 items assessing different depressive symptoms. Each item ranges from 0 to 
2 (0-the symptom is not present, 1 – the symptom is present intermittently, 2 the symptom is 
constantly present; a- the symptom can not be assess). It equally assesses psychological and 
physical symptoms associated often with depression in AD. The total score ranges from 0 to a 
maximum of 38 points 
216
.  
Different cut-off points have been proposed for measuring depression in patients with and 
without dementia. In the original publication a total score above 7/8 has been suggested as 
cut-off, but no sensitivity, specificity, positive and negative likelihood ratios and accuracy 
values were calculated for that cut-off point or other cut-off points 
216
. Cut-off points with the 
best sensitivity, specificity and accuracy vary among patient populations, cultural differences 
and study designs
220
. For example in a nursing home Norwegian population a cut-off 8/9 has 
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the best accuracy for diagnosing ICD-10 major depression, a cut-off 10/11 has the best 
accuracy for DSM-IV-TR major depression while a cut-off 6/7 has the best accuracy for 
diagnosing depression in AD using the Provisional Criteria for Depression in Alzheimer’s 
Disease
221
. Kørner et al. found the best accuracy for a cut-off 6/7 in a Danish out –patient 
population with and without dementia
218
. Knapskog et al. proposed several cut-off points for 
patients with and without dementia in a memory clinic cohort
222
. They suggested that the cut-
off with the best sensitivity and specificity is 5/6; while the cut-off 7/8, which is widely used 
in clinical practice has good psychometric properties  (sensitivity 60, specificity 79 and 
accuracy 72) for diagnosing ICD-10 major depression
222
. 
It is very important that the staff is trained to use CSDD. A study in nursing home population 
found a relatively low recognition of depressive symptoms when the CSDD was 
administrated by the staff in nursing homes compared with trained psychiatrists
223
.  
CSDD have 6 subscales and the assessed symptoms are:  
A. Mood Related Signs (anxiety, sadness, lack of reactivity to pleasant events, irritability) 
B. Behavioural Disturbance (agitation, retardation, multiple physical complaints, acute loss of 
interest) 
C. Physical Signs (appetite loss, weight loss, lack of energy) 
D. Cyclic Functions (diurnal variation of mood, difficulty falling asleep, multiple awakenings 
during sleep, early morning awakenings) 
E. Ideational Disturbance (suicide, self-depreciation, pessimism, mood congruent delusions) 
 
 Geriatric Depression Scale (GDS)224 
This was designed mainly to assess depressive symptoms in older people. It is relatively easy 
to use and it takes around 5-10 minutes to administer. The original version includes 30 items, 
but short versions like GDS-15, GDS-10 and GDS-4 have been developed
225
. There is also a 
self-administrated version. It focuses only on affective symptoms of depression. A Swedish 
version; GDS-20 has been developed by adding 5 items about somatic symptoms of 
depression to the GDS-15 version
226
. 
 Montgomery Asberg Depression Rating scale (MADRS).227  
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MADRS is one of the most used scales for assessing depression. It takes around 15-20 minute 
to administer. Items focusing on the affective and psychological symptoms have an increased 
preponderance than items focusing on somatic symptoms; thus it can be less useful in 
assessing depression in dementia. It is, however preferred in interventional research for its 
sensitivity to changes in depressive symptoms.  
 Hamilton Depression Rating Scale (HAM-D)228 
 It is a useful scale in assessing the severity of depression symptom. It is a semi-structured 
interview based on self-reported symptoms. It takes around 20-30 minutes to administer.  
Like MADRS, it is less useful in assessing depression in dementia.  
 Neuropsychiatric inventory (NPI)229 
NPI assesses frequency and severity of behavioural symptoms in AD and major dementia. A 
question about depressive symptoms is included. It takes around 10 minutes to administer it 
to a carer.  
 Behavioural pathology in Alzheimer’s disease (BEHAVE-AD).230 
This scale is designed to assess the presence of neuropsychological symptoms in AD. As NPI 
it takes around 10 minutes to administer to a caregiver or an informant and a question about 
presence of depressive symptoms is included. 
Scales assessing more affective symptoms as MADRS, HAM-D and GDS-15, GDS-10, 
GDS-4 are better correlated among themselves
225
 
231
, while a relatively poor correlation had 
been recently reported between CSDD and MADRS
220
. Moreover, use of MADRS had a 
better accuracy in predicting major depression assessed by ICD-10 in a memory clinic 
population
222
. 
In AD, the scoring of scales based on self-reported depressive symptoms such as MADRS, 
GDS and HAM-D can be influenced by the patient’s communication skills, insight, and 
ability to abstract thinking. Scales as NPI and BEHAVE-AD mainly based on carer reports 
may be influenced by carer’s mood and perceived burden232. Scales as NPI and BEHAVE-
AD assess mainly mood symptoms as sadness, while CSDD includes other depressive 
symptoms
233
.  
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1.2.6 Diagnosis of depression in Alzheimer’s disease  
Symptoms of depression and AD overlap, therefore diagnosis of depression in AD may be 
challenging. In prodromal AD cognitive symptoms coexist with neuropsychiatric symptoms 
such as depressive mood, social withdrawal, apathy etc
234
.  
It was suggested that DSM criteria for major depressive disorder are not useful to diagnose 
depression in AD
154
, but are used to diagnose depression in prodromal AD
235
. In DSM 5 no 
criteria for depression in AD have been proposed. 
In 2002 Olin JT et al. proposed clinical diagnostic criteria for depression of AD: National 
Institute of Mental Health provisional diagnostic criteria for depression in AD (PDC-dAD)
154
. 
The proposed criteria are based on the DSM IV criteria for major depression. The authors 
reduce emphasis on verbal communication and include new criteria as irritability and social 
isolation. To meet these criteria, a patient with AD must have a change in functioning for 2 or 
more weeks characterized by 3 or more of the following symptoms, either depression or 
anhedonia must be one of the symptoms
154
. 
1. Depressed mood (sad, hopeless, discouraged, tearful) 
2. Anhedonia: Decreased positive affect or pleasure in response to social contacts and 
activities 
3. Social isolation or withdrawal 
4. Disruption in appetite 
5. Disruption in sleep 
6. Psychomotor agitation or retardation 
7. Irritability. 
8. Fatigue or loss of energy 
9. Worthlessness, hopelessness or excessive guilt 
10. Recurrent thoughts of death or suicidal ideation 
The PDC-dAD correlates well with DSM IV criteria and has a good sensitivity and 
specificity. However the prevalence of depression in AD was found higher when using the 
PDC-dAD compared to DSM IV criteria for major depression
236
. In a population of 112 AD 
patients with different degrees of cognitive impairment, proportion of depression was 53.5% 
for PDC-dAD, 47.3% for ICD-10 and 34.8% for DSM-IV-TR criteria
237
. 
Scales as CSDD that use a combination of patient and caregiver interviews are more useful 
for measuring the severity of the depressive symptoms in AD. Scales based only on self-
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reported symptoms as MADRS, HAM-D, HADS can be used in assessing depressive 
symptoms in patients with subjective and mild cognitive impairment
238
. CSDD and GDS are 
more commonly used in assessing depression in AD
238
. BEHAVE-D and NPI can be used in 
more severe stages of AD 
239
.  
1.2.7 Treatment of late life depression   
There is a lack of evidence-based treatment recommendations for late life depression
240
. In 
clinical practice the preferred strategy is an antidepressant treatment
241
 and rarely 
psychotherapy
242
.  
Several studies suggest that antidepressant drugs and lithium are neuroprotective
184,243
 and 
can induce neurogenesis in mice and increase BDNF signalling
244,245
. Other studies have 
found that antidepressants are associated with reduced hippocampal volume
246
. 
Antidepressant treatment as by citalopram has been found to reduce CSF Aβ levels 247 and 
delay onset of dementia and increase life span in patients with Down syndrome
248
. In 
contrast, a recent retrospective cohort study reported that antidepressant treatment might 
increase the risk for developing AD
249
.  
Several studies suggested that hippocampal atrophy, severe white matter lesions and severe 
cognitive impairment are associated with poor response to antidepressant treatment in 
patients with late-life depression
184
.   
Antidepressants are generally considered safe. However, several severe side effects have been 
reported. Short-term use of has been associated with syndrome of inappropriate antidiuretic 
hormone secretion, occurrence of sinus bradycardia, and increased incidence of torsade de 
pointes cardiac arrhythmias (citalopram)
250
. Long-term use increases the risk for 
osteopenia/osteoporosis and falls (for SSRI)
251,252
 and  cardiovascular toxicity and confusion 
(for tricyclic antidepressants)
250
. 
Although all classes of antidepressant treatment are equally efficacious in treating late life 
depression
253
, SSRIs, venlafaxine or mirtazapine are most commonly used
241
. On the other 
hand use of other antidepressant treatments as duloxetine and vortioxetine can improve 
working memory and delayed recall in older people with major depressive disorder over 65 
years of age
254,255
; vortioxetine having the advantage of improving the executive 
functioning
255
. Citalopram, otherwise a commonly used antidepressant, does not improve 
executive functioning associated with major depression disorder in older people over 75 years 
of age
256
.  
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A randomized double placebo trial on late life depression and cognitive impairment 
suggested that augmentation of an antidepressant treatment with AChEI can be beneficial
257
. 
In older people depression is frequently co-occurring with anxiety and sleeping problems and 
therefore anxiolytic and sedative-hypnotic medication (including benzodiazepines) are often 
concomitantly prescribed with antidepressant therapy
258
.   
1.2.7.1 Treatment of depression in Alzheimer’s disease  
There is evidence that psychosocial interventions are significantly beneficial in preventing
259
 
and treating depression in MCI and AD
 94,121
. Such interventions can be problem adaptation 
therapy and supportive therapy for cognitively impaired patients
260
. Other interventions such 
as music and reminiscence therapy, cognitive stimulation, conversation and physical activity 
may also reduce severity of depressive symptoms in AD 
94,121
. However, a randomized 
intervention study found that early psychosocial interventions in AD such as counselling, 
education and social support had little effect on patients’ well-being and did not delay 
institutionalization
261
. 
Although non-pharmacological interventions have been found useful in treating depression in 
AD, antidepressant treatment remains the first choice therapy in clinical practice.  
A Finish registry-based study found that use of antidepressant treatment in community 
dwelling patients with AD is three times that used in community dwelling individuals without 
AD (29.4% versus 10.7%)
262
. The evidence is weak for use of antidepressant treatment for 
depression in AD. Several studies reported benefit of antidepressant treatment
263–267
, while 
more recent studies did not support such benefit
189,268–271
. A Cochrane meta-analysis 
concluded that there are no benefits from use of antidepressant treatment in people with 
established AD and depression
189,272
. The most prescribed antidepressants are SSRI and 
mirtazapine 
262,273
. Little is known about use of antidepressant treatment in preclinical stages 
of AD. 
Electroconvulsive therapy is considered efficacious in treatment of major depression in older 
people. However its effects on depression in AD patients are less well understood. It has been 
suggested that electroconvulsive therapy can be beneficial in treating major depressive 
disorder in patients with AD; in most of the cases the associated memory impairment being 
transitory
274
.   
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Table 3: Depression and the risk for conversion from Mild Cognitive Impairment to Alzheimer’s disease or dementia 
 Number 
MCI 
Convertors  to 
AD or dementia 
Depressed 
patients   
(baseline) 
Definition 
depression 
Age  Duration  
follow up 
(years) 
Source Depression risk factor  
Modrego et al. 
2004 
235
 
114 AD:59 (51.7%) 41 (36%) DSM IV (≥5 
symptoms 
72.8 3   MC Yes (RR:2.6, 95%CI: 1.8-3.6)  
Gabryelewicz  
et al. 2007
275
  
105 Dementia:23 
(21.9%)  
AD :19 (18.1%) 
Mean 
MADRS=9.8 
MADRS  
MDD excluded  
69.3 3  clinic Yes (higher MADRS baseline 
scores among convertors) 
van der 
Mussele 2014
150
 
193 AD:109 Mean CSDD 
14.3 
CSDD 
GDS-30 
74.9 3.8 MC Yes (HR: 2.06; 95% CI:1.2–3.4) 
Teng et al. 
2007
276
   
51 AD:12 (23.5%)  20 (39%) dNPI 73.8 2  MC Yes (67% of convertors and 31% 
non convertors had depression) 
Devier et al. 
2010
277
  
148  AD: 39 (26.4%) Mean HAM-D: 
4.7  
HAMD-17  
MDD excluded 
67.1 5.1  MC  No (RR: 0.99; p:0.8)  
Ramakers et al 
2009
148
 
263  AD:79 (30%) 
Other dementia 11 
Mean HAMD-
17: 9.0 
HAMD 17 69.9 5.4  MC  No (OR 0.62, 95% CI 0.38–1.03)  
Vicini Chilovi 
et al .2009
278
 
124 AD:23 
Other dementia 5 
38 (30.7) 
 
DSM IV 71.2 2  MC No (OR:0.10; 95% CI 0.02-0.4) 
Gallagher et al. 
2011
279
  
161  AD: 69 (42.8%) 41 (25.5%) BEVAHE-AD 
b
 73.7 2.2 
 
MC No(19% of convertors and 30% 
non convertors had depression) 
Mackin et al. 
2012
280
 
405 Dementia 103 
(45.3) 
223 (55%) 
SSD 
GDS-15 74.8 3 MC No (βyears:converter = 0.09, p = 
0.2) 
Chan et al. 
2010
281
  
321  Dementia: 
51 (15.9%) 
54 (16.8%) dNPI 77.5 2  PB 
 
Yes (OR:2.40 95%CI: 1.05–5.5) 
Richard et al. 
2013 
282
 
320 AD: 54 (17%) 
Other dementia 13  
96 (23.1%) CES-D 77.2 5.1  PB Yes (HR:1.9, 95%CI:1.0-3.6) 
Artero et al. 
2008
283
 
2879 
 
AD:122 (4.23) 
Other dementia 
67 (2.32) 
Depressive 
symptoms16% 
MDD:2.4% 
CES-D and 
DSMIV 
74.6 4  PB 
 
Yes (OR = 2.0, 95% CI 1.1 -3.6)  
MC: memory clinic, PB: population based, MDD major depression disorder, SSD: subsyndromal depression, NS not specified, RR: risk ratio, OR: odds ratios, HR 
hazard ratio, p: p-value, DSM: Diagnostic and Statistical Manual of Mental Disorders GDS: geriatric depression scale, CSDD: Cornell Scale for Depression in 
Dementia, MADRS: Montgomery Åsberg depression rating scale, CES-D Center for epidemiologic studies depression scale 
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Table 4: Associations between CSF biomarkers and depression 
Reference CSF Population Age Depression 
measures 
Depression associated with  Design  
Skogseth et al. 
2008 
201
 
t-tau, p-tau, Aβ1-42 AD:32 74.0 MADRS No associations with CSF t-tau, p-tau, Aβ1-42 
(AD patients) 
Clinic, cross 
sectioal 
Kramberger et 
al. 2012
200
 
t-tau, p-tau, Aβ1-42 AD:90 
SCI:92 
67.6 CSDD Lower CSF t-tau (AD patients) 
Lower CSF t-tau and p-tau (SCI patients) 
Clinic, cross 
sectioal 
Auning et al. 
2015
284
 
t-tau, p-tau, Aβ1-42 SCI:22 
MCI:38 
60.0 GDS-15items No associations with CSF t-tau, p-tau, Aβ1-42 
(SCI and MCI patients) 
Clinic, cross 
sectional 
Reis et al. 
2012
199
 
t-tau, p-tau, Aβ1-42 Cognitively 
normal: 28 
71 DSM IV  No associations with CSF t-tau, p-tau, Aβ1-42 
(cognitively normal subjects) 
Clinic, cross 
sectional 
Gudmundsson 
et al. 2007 
198
   
t-tau, Aβ1-42, 
CSF/serum albumin 
ratio 
Cognitively 
normal: 84  
72.6 
(only 
women) 
DSM III-R Higher CSF Aβ1-42 levels 
Higher CSF /serum albumin ratios  
(cognitively normal subjects) 
Population 
based, cross 
sectional 
Pomara et al. 
2011
197
 
t-tau, p-tau, Aβ1-42, 
F2-isoprostane 
Cognitively 
normal: 47 
67.3 DSM IV Lower CSF Aβ1-42 levels 
Higher CSF F2-isoprostane 
No associations with CSF t-tau, p-tau 
(cognitively normal subjects) 
Volunteers, 
cross 
sectional 
Diniz et al. 
2014
215
 
t-tau, p-tau, Aβ1-42, 
BDNF 
MCI :10 
Cognitively 
normal: 40 
69.7 DSM IV-TR Lower CSF BDNF levels 
No associations with CSF t-tau, p-tau, Aβ1-42 
(MCI with depression versus cognitively 
normal with and without depression) 
Clinic, cross 
sectional 
Vermeiren et 
al. 2013 
285
 
aspartate, 
glutamate, 
glutamine, glycine, 
taurine, proline 
AD:202 80.4 CSDD Lower CSF taurine levels 
No associations with other CSF amino acids 
(AD patients) 
Clinic, cross 
sectional 
AD: Alzheimer’s disease, SCI: Subjective cognitive impairment, MCI: mild cognitive impairment, t-tau: total tau, p:tau : phosphorylated tau, Aβ1-42: 
Amyloid beta, DSM: Diagnostic and Statistical Manual of Mental Disorders GDS: geriatric depression scale, CSDD: Cornell Scale for Depression in 
Dementia, MADRS: Montgomery Åsberg depression rating scale, MDD major depressive disorder.  
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Table 5: Neuroimaging of depression in AD 
Reference Imaging 
modalities 
Population Age Depression 
measures 
Depression associated with  Design  
Lebedeva et 
al. 2014
286
 
MRI cortical 
thickness 
AD:148 
(ADNI cohort) 
AD:41  
(KI cohort)  
76.0 
(ADNI cohort) 
66.0 
(KI cohort) 
GDS 
(ADNI 
cohort) 
CSDD  
(KI cohort) 
Cortical thinning in temporal and 
parietal regions 
Negative correlation between 
cortical thickness and CSF total 
tau  (AD patients) 
Clinic, Cross 
sectional 
Lebedev et 
al. 2014 
205
 
MRI cortical 
thickness 
AD:30 76.5 MADRS Cortical thinning in prefrontal and 
temporal areas. (AD patients) 
Clinic, cross 
sectional 
Zahodne et 
al. 2013
203
 
MRI cortical 
thickness 
MCI: 334  
(ADNI cohort) 
74.9 NPI-Q Reduced entorhinal thickness at 
baseline 
Accelerated atrophy in anterior 
cingulate cortex at follow-up 
(MCI patients) 
Clinic, 
Prospective 
30.5 months 
follow up 
Hu et al. 
2015
287
 
MRI: GM 
volumes, cortical 
thickness 
MCI: 202 
AD: 85 
(ADNI cohort) 
74.8 NPI-Q Decreased gray matter volumes in 
left middle frontal cortex (AD and 
MCI patients) 
Clinic, Cross 
sectional 
Auning et al. 
2015
284
 
MRI: GM 
volumes, cortical 
thickness 
DTI, FDG-PET 
SCI: 22 
MCI: 38 
60.0 GDS No associations with pathological 
imaging (SCI and MCI patients)  
Clinic, cross 
sectional 
Enache et al. 
2015 
288
 
MRI visual 
assessment, 
hippocampal 
volume 
SCI:139 
MCI:130 
AD:99 
64.6 CSDD Smaller right and left hippocampi 
(SCI patients) 
Less atrophic right and medial 
temporal lobe (AD patients) 
Clinic, cross 
sectional 
Lee et al. 
2015
289
 
MRI: WMH 
volumes 
AD: 93 76.1 DSM IV 
GDS 
 Frontal WMH (AD patients) Clinic and 
community 
based, cross 
sectional 
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AD: Alzheimer’s disease, MCI: mild cognitive impairment, LLD: late life depression, ADNI : cohort from Alzheimer’s Disease Neuroimaging Initiative; 
KI: cohort from Karolinska University Hospital cohort; GDS: geriatric depression scale, CSDD: Cornell Scale for Depression in Dementia,  HAM-D: 
Hamilton rating scale for depression, GM volumes: gray matter, DTI: Diffusion tensor imaging , WMH: white matter hyperintensities, WML:white matter 
lesions,  PET: positron emission tomography, FDG-PET: fluoro-deoxy- glucose positron emission tomography, PiB: [11C] Pittsburgh Compound B, NPI 
Neuropsychiatric Inventory, NPI-d Neuropsychiatric Inventory-depression question , Aβ: amyloid beta 
Soennesyn et 
al. 2012
290
 
MRI: WMH 
volumes 
AD:59 
 
77 MADRS Higher volumes of total and 
frontal deep WMH (AD patients) 
Clinic, 
prospective 
Tsai et al. 
2013
291
 
MRI 
spectroscopy 
AD: 26 75 GDS  Higher choline/creatine ratio in the 
left dorsolateral prefrontal cortex 
Higher myo-inositol/creatine ratio 
in the left and right cingulate gyri 
(AD patients) 
Clinic, cross 
sectional 
Chung et al. 
2015
292
  
18
F-florbetapir-
PET 
 
MCI+Lifetime 
Depression: 39 
(ADNI cohort) 
70.5 GDS, NPI Increased Aβ deposition bilateral 
frontal cortex (amnestic MCI 
patients with lifetime 
depression) 
Clinic, cross 
sectional 
Donovan et 
al. 2015 
195
 
MRI: GM 
volumes  
FDG-PET 
11C PiB-PET 
Healthy 
controls 248 
74.0 GDS 
Depressive 
symptoms 
Lower hippocampal volume  
No associations with Aβ 
deposition (healthy controls with 
depressive symptoms) 
Community 
based, cross 
sectional 
Madsen et al. 
2012
194
 
11C PiB-PET LLD:28 
(moderate to 
severe) 
61.3 HAM-D<8,  
GDS<5 no 
current 
episode 
No associations with Aβ 
deposition (LLD patients, no 
current episode) 
Clinical, cross 
sectional 
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2 AIMS  
General aims: 
To explore the associations between depressive symptoms and biomarkers of amyloid 
deposition and neuronal injury in older people with and without AD. 
To explore the associations between antidepressant treatment in pre-dementia stages and 
mortality risk after a dementia diagnosis.  
To explore the associations between CAIDE Dementia Risk Score and biomarkers of 
amyloid deposition, neuronal injury and small vessel disease. To evaluate the role of CAIDE 
Dementia Risk Score to predict dementia in a memory clinic population. 
Specific aims: 
Study I:   
 To explore the associations between depressive symptoms and CSF biomarkers of 
amyloid deposition, tau pathology in older people with and without AD  
Study II:  
 To explore the associations between depressive symptoms and medial temporal lobe 
atrophy and hippocampus atrophy in older people with and without AD  
Study III: 
 To describe the use of antidepressant treatment in patients with dementia 
  To explore the association between mortality risk and use of antidepressants three 
years before diagnosis of dementia  
Study IV:  
 To explore the associations between CAIDE Dementia Risk score and biomarkers of 
amyloid deposition, neuronal injury, small vessel pathology 
 To evaluate capacity of CAIDE Demntia Risk Score to predict dementia in a memory 
clinic cohort  
Supplementary analysis: 
 To explore the risk of developing dementia in patients with depressive symptoms and 
in patients on antidepressant treatment in a memory clinic cohort 
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3 MATERIAL AND METHODS 
Data used for this thesis is derived from 2 projects: a large memory clinic database from 
Karolinska University Hospital Huddinge and Swedish Dementia Registry (SveDem). 
3.1 MEMORY CLINIC KAROLINSKA UNIVERSITY HOSPITAL HUDDINGE 
SWEDEN  
Patients at risk to develop dementia are referred from general practitioners and other 
specialties to the Memory Clinic Karolinska University Hospital Huddinge. Patients younger 
than 65 years of age are referred from the whole Stockholm’s area. Approximately 550 new 
patients are seen in the clinic every year with a total number of approximately 3500 follow up 
visits per year. 
Our database includes a total of 1760 patients: 1588 new patients referred consecutively 
between 2007-2010 and additional 172 patients referred between 2001-2004, 2011-2012 and 
from 2 imaging studies. 
3.1.1 Study population  
3.1.1.1 Inclusion and exclusion criteria   
The base population for study I consisted of 1,154 outpatients referred to the Memory Clinic 
between 2007 and 2009. For study II, 57 patients from another imaging study referred 
between 2001 and 2004 were added. New data had been collected and the base population for 
study IV consisted 1,703 outpatients referred between 2007-2012. Figure 6 presents a flow 
chart of the whole cohort included and excluded in each study.  
Inclusion and exclusion criteria for study I, II and IV are described in Table 6.  
Table 6: Inclusion and exclusion criteria for studies I, II and IV. 
 Inclusion criteria  Exclusion criteria  
Study I  
1. Age 60 years or older  
2. Complete data on CSDD 
3. CSF biomarkers: Aβ1-42, t-tau, p-
tau181 
4. Diagnosis of AD and SCI  
1. Diagnosis of MCI or other 
dementia 
2. Disease with expected reduced 
survival time 
Study II 
1. Age 55 years or older  
2. Complete data on CSDD and use of 
antidepressant treatment (yes/no) 
3. MRI or CT available coronar 
section 
1. Diagnosis of other dementia 
2. Disease with expected reduced 
survival time 
3. Psychiatric disorders or brain 
injuries significantly affecting 
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4. Diagnosis of AD, MCI and SCI cognitive performance 
Study IV and 
Supplementary 
analysis 
1. Age 40 years or older  
2. Complete data on CAIDE 
Dementia Risk Score  
3. CSF biomarkers: Aβ1-42, t-tau, p-
tau181 
4. Diagnosis of AD, MCI and SCI 
 
1. Dementia 
2. Development of dementia within 
one year from baseline  
3. Medical condition affecting CSF 
and MRI assessment (multiple 
sclerosis, large strokes, 
hydrocephalus, brain tumors) 
SCI: subjective cognitive impairment, MCI: Mild Cognitive impairment, AD: Alzheimer’s 
disease, CSDD: Cornell Scale for Depression in Dementia, CSF: Cerebrospinal Fluid, MRI 
magnetic resonance imaging 
3.1.1.2 Follow up (Study IV) 
SCI and MCI patients with high risk for cognitive decline as judged on multidisciplinary 
diagnostic rounds are invited for follow-up visits after the initial assessment. The planned 
follow up is according to the protocol at the Memory Clinic. 
Figure 6: Flow chart presenting the memory clinic sample included and excluded in 
Studies I, II, IV. SCI: subjective cognitive impairment, MCI: Mild Cognitive impairment, 
AD: Alzheimer’s disease, CSDD: Cornell Scale for Depression in Dementia, WMC: white 
matter changes, CSF: Cerebrospinal Fluid, MRI magnetic resonance imaging,  
1154 consecutive out-patients referred to Memory Clinic (2007-2009)
5 7 SCI +AD
included from
another imaging
study (2017-2004)
434 consecutive patients 2010  and 115  referred between  
2011-2012 collected for an imaging study  
=> 1703 patients  
Study I  
183 SCI and  AD , 60 +         
       CSDD 
       CSF biomarkers  
Study I I  
3 6 8 SCI, MCI, AD , 55+ 
      CSDD 
      MRI with va MTL 
5 7 MRI manual delineation  
hippocampal volume  
Study	 IV
7 2 4 SCI and MCI  
       CAIDE Dementia Risk Score and  
       CSF biomarkers 
3 1 0  APOE  
5 2 9 MRI images rated for atrophy and 
WMC 
6 0 6 CSDD 
9 7 2 excluded: 
449 younger than 60  
253 patients with MCI  
150 missing data on CSDD 
65  missing data on  CSF biomarkers 
55 other dementia disorders than  AD  
843 excluded: 
213 younger than 55 
305 missing data on CSDD  
288 missing data on MRI  
35 other dementia disorders than AD  
2 life threatening diseases  
9 7 9 excluded: 
53 progressed to dementia within on year 
326 missing data on CSF 
89 missing data for CAIDE Dementia Risk Score  
4 with conditions affecting CSF or MRI measurements 
494 with dementia disorder 
 
3 2 4 with a minimum one year follow up  
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In study IV, follow up data were collected in March 2015. Altogether, 324 (44.8%) patients 
out of 724 were followed-up for at least one year (mean ± SD: 2.9 ± 11.6 years). At the end 
of the follow up, 100 (30.9%) patients progressed to dementia (78 (24.1%) patients 
progressed to AD and 22 (6.8%) patients progressed to other dementia disorders). 110 out of 
the 324 patients had SCI at baseline and at the end of the follow up 72 (65.5%) remained as 
SCI, 24 (21.8%) progressed to MCI, 14 (12.7%) progressed to dementia disorders (10 
patients with AD and 4 patients with other dementia disorders). 214 out of the 324 patients 
had MCI at baseline and at the end of the follow up 15 (7.0%) converted to SCI, 113 (52.8%) 
remained as MCI, 86 (40.2%) progressed to dementia disorders (68 patients with AD and 18 
patients with other dementia).  
3.1.2 Assessment program  
Participants in studies I, II and IV underwent a standard protocol that included: 
1. General Demographic information (age, gender, mother language, occupation and 
socioeconomic status) 
2. Complete medical examination including: 
 Interview performed by a physician with the patient and informant 
 Neurological examination 
 Vascular risk profile  
 Information on previous depression and current use of antidepressants 
 Depressive symptoms measured with severity scales: CSDD or GDS   
 Functional status by proxy (Informant Questionnaire on Cognitive Decline in 
the Elderly-IQCODE)
47
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 Neuropsychological tests     
 Speech pathologist assessment* 
 Routine blood chemistry (Thyroid hormones, homocysteine, vitamin B12) 
 APOE genotype 
 CSF (Aβ 421-42, t-tau, p-tau181) values 
 EEG*  
 MRI: (visual assessment of brain atrophy) 
 FDG-PET*  
 Amyloid-PET* 
 DaT SCAN* 
*Performed for particular clinical indication 
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3.1.2.1 Diagnostic criteria for Alzheimer’s disease (AD), mild cognitive impairment 
(MCI) and subjective cognitive impairment (SCI)  
Diagnoses of AD, MCI and SCI were established after a consensus meeting with specialists 
in neurology, geriatric medicine and psychiatry, nurses, neuropsychologists and speech 
therapist taking into account all available information. 
Patients were diagnosed with dementia disorders (AD and other types) according to the 
International Classification of Diseases –Tenth (ICD-10).  
Patients were diagnosed as MCI according to the revised International Working Group 
criteria
56
. Patients were diagnosed as SCI if neither dementia disorder nor MCI criteria were 
fulfilled. In patients classified as SCI, neuropsychological tests did not show evidence of 
cognitive impairment although the patients and their informant reported some degree of 
impairment in the patients’ cognitive performance compared to the premorbid level. 
3.1.2.2 Assessments of cognitive function  
1. Global cognition (Mini Mental State examination -MMSE294- and Full Scale IQ -
FSIQ*)  
2. Language (Similarities*, Information* and Vocabulary*) 
3. Perceptual motor function (Rey complex figure copying295, Block design*, Matrix*) 
4. Short-term memory (Digit span*) and Episodic memory (Rey auditory verbal 
learning test learning and retention after 30 minutes, Rey complex figure immediate 
retention
295
) 
5. Executive function and complex attention (Trail making test A and B295 and Digit 
symbol*) 
* Wechsler Adult Intelligence Scale revised version (WAIS -R)
296
 for patients referred in 
2007, and Wechsler Adult Intelligence Scale III version (WAIS-III)
297
 for patients referred 
between 2008-2010.  
3.1.2.3 Depressive symptoms  
Depressive symptoms were assessed using Cornell Scale of Depression in Dementia (CSDD), 
which has good psychometric properties in both individuals with and without dementia
216
 
217
. 
The CSDD was completed by a licensed geriatrician or psychiatrist, or a trained geriatric 
nurse specialist.  
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Data on antidepressant treatment at the clinic assessment was collected retrospectively from 
patients’ records.  History of depression is self reported or documented by a physician and 
coded as depression, using ICD-10 codes for depression.  
We defined depressive symptoms using recommended cut-offs: 
 CSDD ≥ 7 218 –study I 
 CSDD ≥ 8 216- study II  and supplementary analysis (when calculating associations 
between depression and risk to develop dementia) 
 CSDD ≥ 8 or antidepressant therapy 298- study II. It have been suggested that 
information on use of antidepressant treatment can improve the classification 
accuracy 
298
. 
3.1.2.4 Assessment of CAIDE Dementia Risk Score  
For study IV we used a modified version of the CAIDE Dementia Risk Score relatively 
similar with the version used in the validation study by Exalto et al
25
. Variables “cholesterol 
levels and systolic blood pressure” were replaced with diagnosis of hyperlipidaemia or 
hypertension. Physical activity was excluded due to lack of systematic recoded data. The total 
maximum points for CAIDE Dementia Risk Score version without APOE was 14 points and 
version with APOE was17 points
25
 (Annex). CAIDE Dementia Risk Score was scored 
retrospectively by an experienced research clinician based on available data, blind to CSF and 
MRI results. 
3.1.2.5 Cerebrospial fluid (CSF) analyses 
CSF was obtained by lumbar puncture. CSF Aβ1-42, t-tau and p-tau181 were measured using 
procedures previously described for Aβ1-42
299
 and for t-tau and p-tau181
300
.  
3.1.2.6 APOE genotype 
APOE genotype was analyzed from blood leucocytes using polymerase chain reaction and 
HhaI digestion
301
.   
3.1.2.7 Image acquisition  
The neuroradiologic investigations used for these studies were performed as part of the 
dementia assessment. Magnetic resonance imaging (MRI) and computer tomography (CT) 
scans are performed at the Department of Radiology, Karolinska University Hospital or in 
other different radiology departments and hospitals in Stockholm and neighbouring counties, 
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with different equipment and protocols. All images were collected in a common electronic 
database at the Department of Radiology, Karolinska University Hospital-Huddinge.  
 Visual assessment of the medial temporal lobe (vaMTL)(fig 1) (study II and 
Study IV) 
Medial temporal lobe was visually assessed on T1 weighted oblique coronal sections of MRI 
and CT images, since a good intra-observer agreement had been shown between multi-
detector row CT and 1.5 Tesla MRI for vaMTL on the left and right hemisphere
302
. Medial 
temporal lobe was rated using Scheltens scale
77
, which is based on a visual estimation of 
volume of the medial temporal lobe. The visual assessment includes hippocampus, dentate 
gyrus, subiculum, parahippocampal gyrus, entorhinal cortex and surrounding CSF spaces 
such as the temporal horns and choroid fissure. This is a 5-point scale, which ranges from 0 
(no atrophy) to 4 (end stage) and it is applied to the right and left hemispheres separately.   
In study II medial temporal lobe was visually assessed on 295 (80.16%) MRI and 73 
(19.84%) CT scans. Medial temporal lobe volume is age dependent; we considered as normal 
vaMTL scores 0-1 in persons less than 70 years, vaMTL ≤ 2 between 70-80 and vaMTL ≤ 3 
over the age of 80 according to the findings from our group
303
. Medial temporal lobe atrophy 
(MTA) was defined as vaMTL scores above the age reference values. 
In study IV 529 MRI scans were rated for medial temporal lobe atrophy, parietal atrophy, 
global cortical atrophy- frontal subscale and white matter changes. No cut off points on the 
Scheltens scale were used in study IV. MTA was obtained by calculating the average score 
on Scheltens scale 
304
, and mean scores 2.5, 3 and 4 were grouped together. 
 Manual tracing : hippocampal volume (study II) 
Manual tracing of hippocampal volumes was performed on MRI scans following the protocol 
proposed by Malykhin et al.
305
.  Manual tracing of hippocampal volume has a high reliability 
and is considered the gold standard method for measuring hippocampal volume. The total 
intracranial volume (TICV) was obtained using a stereologic point-counting technique, 
consisting of normal tracing of the TICV on every forth section, following the landmarks 
proposed by Eritaia et al
306
 image with the manual tracing technique. Right and left 
hippocampal volumes (cm3) were separately delineated and normalized by TICV using Jack 
CR Jr et al
307
 method: 
Volume (adjusted) = Volume (observed) – β [slope of the regression line of 
hippocampal volume regressed on TICV]*(TICV the subject TICV – TICV sample mean) 
 50 
In study II hippocampus was manually delineated on 57 MRI scans. 
 Visual assessment of parietal lobe atrophy (study IV) 
Parietal atrophy (PA) was visually assessed by combining T1 weighted axial, T1 weighted 
coronal and axial FLAIR sequences using Koedam score
308
. Koedam score is a 4-point scale, 
which ranges from 0 (no atrophy) to 3 (severe atrophy). 
 Visual assessment of frontal atrophy (study IV) 
Frontal atrophy was visually assessed on a FLAIR sequence using a subscale of global 
cortical atrophy –frontal region (GCA-F)309. GCA-F is a 4-point scale, which ranges from 0 
(no cortical atrophy) to 3 (severe atrophy). 
 Visual assessment of white matter changes (WMC) (study IV) 
 WMC were visually assessed on transverse FLAIR images using the Fazekas scale
310
. The 
scale provides an overall impression of the presence of WMC in cerebrum. Fazekas scale is a 
4-point scale, which ranges from 0 (no white mater hyperintensity changes) to 3 (large 
confluent white matter hyperintensity changes). 
Experienced raters (Lena Cavallin and Bram B. Zandbelt) performed the manual tracing of 
hippocampal volume and visual assessment of vaMTL, parietal, frontal atrophy and WMC. 
Both raters were blinded to clinical diagnosis, CSDD scores, antidepressant therapy and 
CAIDE Dementia Risk Score. Intrarater reliability was assessed for vaMTL, was 0.81 on 
right side and 0.78 on left side
76
 and intraclass correlation coefficient for manual 
hippocampus tracing was 0.91
311
.  
3.2 SWEDISH DEMENTIA REGISTRY AND SWEDISH PRESCRIBED DRUG 
REGISTRY  
In study III the cohort included was based on data from two national registries: Swedish 
Dementia Registry (SveDem) and the Swedish Prescribed Drug Register. The databases 
were merged using the unique social security number assigned to each Swedish citizen. 
Information on deaths occurring within the cohort during the study period was obtained 
through record linkage with the national patient registry. The end of follow up for the 
outcome was the date of death or 31 October 2013.  
SveDem, Swedish Dementia Registry was established in May 2007 with the aim to ensure 
the quality of the diagnostic workup, treatment and care of patients with dementia disorders 
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in Sweden 
312
. Age, gender, demographic data, Body Mass Index, MMSE scores, diagnostic 
procedures, type of dementia disease and treatment are recorded at the time of dementia 
diagnosis in primary or specialist care.  SveDem covers almost 60% of primary cares and 
almost 90% of memory clinics across Sweden
312
. Information on death is collected from the 
national population registry. Diagnoses of dementia diseases are coded as AD, mixed 
dementia (MixedD- vascular and Alzheimer), vascular dementia (VaD), frontotemporal 
lobe dementia, Dementia with Lewy bodies, Parkinson’s disease dementia, unspecified 
dementia (Unspecified) and other dementia (Others). Although the diagnoses of dementia 
disorders registered in SweDem are not neuropathologically validated, in a random sample 
of patients registered in memory clinics the diagnoses were in good agreement with 
medical records
313
.  
The Swedish Prescribed Drug Register was established in 2005 and contains information on 
all drugs prescribed in ambulatory care and dispensed (i.e. drugs were collected by the 
patient at the pharmacy) at Swedish pharmacies to the entire Swedish population. It is 
administrated by Centre for Epidemiology at the National Board of Heath and Welfare in 
Sweden. The register contains the following data: personal identification number, age, 
gender, address, substance, brand name, formulation and package; dispensed amount, 
dosage, expenditure and reimbursement, date of prescribing and dispensing, the practice 
(primary Health care center or hospital clinic) that has issued the prescription and the 
prescriber’s profession314. All drugs are classified according to the Anatomical Therapeutic 
Chemical (ATC) classification system
314
. 
3.2.1 Subjects  
Data from The Swedish Prescribed Drug Register was available between 1
st
 July 2005 and 
31
st
 August 2013. We used information on the total number of medication and all 
antidepressants dispensed at four specific time points: at the time of a diagnosis of dementia 
disorder and inclusion in SveDem, at the first, second and third year prior to the date of 
diagnosis of dementia and inclusion in SveDem.  
 We used the following ATC codes for antidepressant and other drug classes approved in 
Sweden in 2014 (see http://www.whocc.no/atc_ddd_index): N05A Antipsychotics, N05B 
Anxiolytics, N05C Hypnotics and sedatives, N06A Antidepressants (N06A A Non-
selective monoamine reuptake inhibitors, N06A B Selective serotonin reuptake inhibitor, 
N06A X Other antidepressants), N06D A Cholinesterase inhibitors, N06D X01 Memantine: 
N-methyl D-aspartate (NMDA) antagonist, Cardiovascular medication (B01 
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Antithrombotic agents, C01 Cardiac therapy, C02 Antihypertensive, C03 diuretics, C07 
Beta blocking agents, C08 Calcium channel blockers, C08 agents acting on the renin-
angiotensin system , C10 Lipid modifying agents). 
The study sample includes patients referred to memory clinics and registered in SveDem 
with a diagnosis of dementia disorders during 1
st
 May 2007 – 31st October 2013 (Figure 7). 
Patients diagnosed in primary care settings were excluded due to inconsistency in 
diagnostic procedures for dementia disorders as compared to specialist units and due to a 
lower coverage of these units in the registry.  Out of 21,991 patients in SveDem with a 
complete data set at diagnosis of dementia disease, 1941 patients registered in SveDem in 
2007 were excluded due to missing or incomplete data on antidepressant use 3 years prior 
to dementia diagnosis, thus 20,050 patients were included.  
3.3 STATISTICAL METHODS 
Statistical analyses were performed with Statistical Package for the Social Science (SPSS 
Inc., Chicago, IL, USA) software versions 20.0 and 22.0 for Windows and Stata software 
version 13 (diagt command was used in study IV). The level of statistical significance was set 
Figure 7: Flowchart with study population in study III  
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to p<0.05 in all analyses. Several statistical analyses were used throughout all 4 studies; 
Table 4 summarizes the outcome variables and the determinants for each study.  
3.3.1 Specific analyses for each study  
Study I  
Patients with SCI and AD were divided into 4 groups based on presence or absence of 
depressive symptoms. Between-group comparisons were made using parametric (Student-t 
test) and non-parametric (chi-square tests, Mann-Whitney) tests as appropriate. Simple 
logistic regression was used to compare the CSF-Aβ1-42, t-tau and p-tau181 values between 
patients with and without depressive symptoms in each diagnostic group. 
To explore the association between CSF-Aβ1-42, t-tau and p-tau181 values and CSDD total 
scores, regression models were built using ordered logistic regression, adjusting for 
cofounders. Model 1 adjusting for age and gender and model 2 adjusting for age, gender and 
MMSE score.  
Study II  
Patients with SCI, MCI and AD were divided in 6 groups based on presence and absence of 
depressive symptoms. Between-group comparisons were made using parametric (Student-t 
test) and non-parametric (chi-square tests, Mann-Whitney, Kruskal Wallis) tests as 
appropriate in each diagnostic group. 
To explore the associations between MTA and depressive symptoms, regression models were 
built using simple logistic regression (MTA yes/no) or ordered logistic regression (taking into 
account the scale for visual assessment of the medial temporal lobe). Odds ratios (OR) and 
95% confidence intervals (95%CI) were estimated between MTA or vaMTL and depressive 
symptoms. All analyses were adjusted for gender, MMSE and years of education. 
To explore the associations between hippocampal volumes manually delineated and 
depressive symptoms, regression models were built using generalized linear model 
(depressive symptoms yes/no) and linear regression (taking into account the whole CSDD) 
scale. Generalized linear model estimated mean and mean differences between hippocampal 
volume in patients with and without depressive symptoms. Linear regression estimated 
standardized beta-coefficients and p-values between hippocampal volume and CSDD. All 
models were adjusted for age, gender, MMSE and years of education.    
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Study III 
Cross sectional data on dispensed antidepressants (yes/no) were available at the third, the 
second and the first year prior to a diagnosis of dementia (e.g. a patient received a diagnosis 
of dementia on 11/11/2011, we have data on use of antidepressant (yes/no) on that day, 
11/11/2011 and on the same day in the first 11.11.2010, second 11.11.2009 and third 
11.11.2008 year prior to a diagnosis of dementia). Summing up our cross-sectional data we 
obtained a dichotomous variable of users and non-users of antidepressants at any time 
during the three-year period prior to a diagnosis of dementia. In addition we classified 
patients as users of antidepressants one, two, or three years out of 3. 
The study cohort was divided in 2 groups: users of antidepressants and non-users of 
antidepressants at the time of diagnosis of dementia disorder, and during the 3 years prior to 
a diagnosis of dementia. Between-group comparisons were made using parametric 
(Student-t test) and non-parametric (chi-square tests, Mann-Whitney, binary logistic 
regression) tests as appropriate in each diagnostic group. Means, standard deviations (SD), 
total numbers and percentages were reported. Person-years (PY) at risk were calculated 
from dementia diagnosis to date of death or end of follow-up, on October 31
st
, 2013. 
To explore the associations between use of antidepressants and time to death, regression 
models were built using Cox regression. Hazard ratios (HR) of death and 95%CI were 
estimated. The analysis was adjusted for average age, average number of medication taken 
during the 3 years prior to a diagnosis of dementia, gender, MMSE at time of diagnosis of 
dementia and living conditions at time of diagnosis of dementia (home or nursing home). 
The analyses performed in the whole cohort included additionally “type of dementia” as a 
categorical covariate in each model.  
Study IV  
CAIDE Dementia Risk Score was categorized into three groups of relatively similar sample 
size: 0-5 points (lower risk, n=301 patients), 6-7 points (intermediate risk, n=214) and 8-14 
points (higher risk, n=209) for the version without APOE; and 0-6 points (lower risk, n=81 
patients), 7-8 points (intermediate risk, n=98) and 9-17 points (higher risk, n=131) for the 
version with APOE. The lower risk category was used as reference in all analyses.  
Based on recent studies suggesting that combinations of CSF biomarkers may be more 
accurate indicators of Alzheimer’s disease than each marker separately315, the Aβ1-42/t-tau and 
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Aβ1-42/p-tau181 ratios were calculated. Zero-skewness log-transformation was applied to Aβ1-
42, t-tau, p-tau181, and Aβ1-42/t-tau and Aβ1-42/p-tau181 ratios.  
Comparisons between included and excluded patients were made using parametric (Student-t 
test) and non-parametric (chi-square tests, Mann-Whitney, Kruskal Wallis) tests as 
appropriate. 
To explore the associations between CSF Aβ1-42, t-tau and p-tau181 values and CAIDE 
Dementia Risk Score regression models were built using linear regression. Standardized beta-
coefficients and p-values were estimated. 
To explore associations between visual assessment scales on MRI (MTA, parietal atrophy, 
frontal atrophy and WMC) and CAIDE Dementia Risk Score, regression models were built 
using ordinal regression. OR and 95%CI were estimated.  Stratified analyses were conducted 
according to diagnosis (SCI or MCI).  
We evaluated the performance of CAIDE Dementia Risk Score (version with and without 
APOE) to predict dementia in patients with available follow up (n=324). Area under the 
receiver operating characteristics curve (AUC) and 95% CI, sensitivity, specificity, likelihood 
ratios for positive and negative tests were calculated. We conducted additional analyses to 
account for missing follow up data: 1) assuming that patients without planned follow-up did 
not develop dementia; and 2) assuming that MCI patients without planned follow-up 
developed dementia. 
Supplementary results 
We used clinical follow up data from study IV to explore the associations between depressive 
symptoms and risk to develop dementia. Additionally we explored the associations between 
use of antidepressant treatment and risk to develop dementia. At baseline 606 patients had 
available data on CSDD and all patients had data on use of antidepressants. The study cohort 
was divided into: patients with and without depressive symptoms. Additionally the sample 
was divided into: users and non-users of antidepressants.  
Between-group comparisons were made using parametric (Student-t test) and non-parametric 
(chi-square tests, Mann-Whitney) tests as appropriate in each diagnostic group. Means, SD, 
total numbers and percentages were reported.  
To explore the associations between depressive symptoms and time to end of the follow up, 
regression models were built using Cox regression. HR and 95%CI were estimated. 
Similarly cox regression models were built to assess the associations between use of 
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antidepressant treatment and time to end of the follow up. Crude and adjusted models for 
age, gender, education, CSF Aβ1-42, t-tau and p-tau181 were made. We present the results 
from the adjusted analysis.  
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Table 7: Statistical analyses used throughout the four studies 
 
 
 
 
 
 
 
 
 
 
 
 
CSDD:Cornell Scale for Depression in Dementia, M1: model 1, M2: model 2, vaMTL: visual assessment of the medial temporal lobe, APOE: 
apolipoprotein E genotype, Aβ1-42: amyloid β1-42, t-tau: total tau, p-tau181: phosphorylated tau at threonine 181, MTA: medial temporal lobe atrophy 
(mean MTA scores of both hemispheres) , GCA-F : global cortical atrophy frontal subscale, WMC:  white matter changes measured with Fazekas scale 
for white matter changes, CAIDE: Cardiovascular Risk Factors, Aging and Dementia Study, LR+: likelihood ratio for positive test, LR-: likelihood 
ratio for negative test
Study       Aims       Outcome Main covariates Other covariates Main statistical 
procedure  
 
Study I 
Associations: depression and CSF 
biomarkers  
Constinuous variable 
CSF Aβ1-42 
CSF t-tau  
CSF p-tau181 
Depressive symptoms 
(yes /no) 
M1: age, gender  
M2 age, gender, MMSE  
Ordinal regression 
 
Study II 
Associations: depression and 
MTA 
MTA yes /no  
vaMTL(scale0-5) 
 
Depressive symptoms 
(yes/no) 
CSDD score 
Gender, MMSE years of 
education 
Logistic regression 
Ordinal regression  
Associations: depression and 
hippocampal volume 
Hippocampal volume Age, gender, MMSE 
years of education 
Generalized linear model 
Linear regression 
 
Study III 
Associations: use of 
antidepressant treatment and 
mortality risk 
Number of days until death 
or end of follow up 
Antidepressants 
(yes/no)  
Antidepressants 3 years 
before dementia (3 
groups) 
Age, gender, total number 
of medication, MMSE, 
living conditions, use of 
antipsychotics 
Survival analysis (Cox 
regression) 
 
Study IV 
Associations: CAIDE Demntia 
Risk Score and CSF biomarkers, 
MTA, WMC, PA, GFA,  
CAIDE LR+LR- 
Continuous variable: CSF 
Abtea42, T-tau, p-tau181 
CAIDE Dementia Risk 
Score (3 groups) 
- Linear regression 
Ordinal regression 
Receiver operating 
characteristic (ROC) 
 
Supplem
entary  
Associations: 
Depressive symptoms/ 
antidepressant treatment and risk 
to develop dementia  
Number of days until 
conversion to dementia or 
end of follow up 
 
Depressive symptoms 
(yes/no) 
 
Antidepressants 
(yes/no) 
 Age, gender, education, 
CSF Aβ, t-tau and p-tau181 
Survival analysis (Cox 
regression) 
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4 ETHICAL CONSIDERATIONS 
Study I, II and IV were approved by the Ethical Committee at Karolinska University Hospital 
in Huddinge and by the Regional Ethical Review Board in Stockholm (DNR: 2010/1817-
31/2, 2011/1987 31/4). All patients provided written consent to use clinical information for 
research. 
Study III was approved by the regional ethical review board in Stockholm (Dnr: 2013/147-
31/2). An additional amendment facilitating the use of both registry and the data related to 
antidepressant treatment was approved (Dnr: 2014/2029-3 2). The data were anonymized 
before statistical analysis.  Patients and their relatives were informed orally and in writing 
about SveDem and could decline participation. 
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5 RESULTS 
5.1  BIOMARKERS OF AMYLOID DEPOSITION, NEURONAL INJURY IN 
DEPRESSION IN ALZHEIMER’S DISEASE 
5.1.1 Cerebrospinal fluid biomarkers  
We found no significant associations between CSDD scores and CSF-Aβ1-42 in our memory 
clinic cohort of 183 patients with SCI (n=92) and AD (n=91) (Figure 8).  
In AD group we found that patients with depressive symptoms have lower CSF t-tau levels 
(p=0.03) than those without depressive symptoms. No significant differences in CSF p-tau181 
or Aβ1-42 levels were found between the groups of AD patients with and without depressive 
symptoms. In the SCI group depressive symptoms were associated with lower CSF t-tau 
(p=0.02) and p-tau181 (p=0.04) levels; No associations were found with levels of CSF Aβ1-42. 
5.1.2  Imaging biomarkers  
The studied sample included 368 patients with SCI (n=139), MCI (n= 130) and AD (n=99). 
We found that in patients with AD, right MTA was associated with decreased OR of 
depressive symptoms (adjusted OR: 0.39 95%CI: 0.16-0.99). Moreover using the score of the 
whole Scheltens scale we found in the AD group decreased OR for having depressive 
symptoms for each increase of 1 point on Scheltens scale (adjusted OR: 0.43 95%CI: 0.19-
0.96) (Figure 9).   
We stratified the analysis based on the age of onset of AD, 47 had an early onset before 65 
years. Patients with early onset AD and depressive symptoms had 0.79 times decreased 
likelihood to present right MTA (OR 0.21; 95% CI 0.05-0.95), while in patients with late 
 
Figure 8. Associations between levels of CSF-Aβ1-42 (A) and CSF t-tau  (B) and depressive 
symptoms in patients with subjective cognitive impairment and Alzheimer’s disease. SCI: 
subjective cognitive impairment, AD: Alzheimer’s disease.  
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onset AD the association between depressive symptoms and MTA was not significant (OR 
0.53; 95% CI 0.15-1.99).  
For 57 patients with SCI (n=32) and AD (n=25), hippocampal volume was manually 
delineated. Patients with SCI and depressive symptoms had more atrophic hippocampal 
volumes (mean values for right 2.60 cm
3
 and left 2.45 cm
3 
hippocampus) compared to SCI 
patients without depressive symptoms (mean values for right 2.88 cm
3
 and left 2.77cm
3 
hippocampus). Mean difference and (p value) were -0.28 cm
3
 (p=0.005) for the right 
hippocampal volume and -0.32 cm
3
 (p=0.002) for left hippocampal volume (Figure 10).  In 
AD, there were no significant association between depressive symptoms and hippocampal 
                   
Figure 10. Associations between right (A) and left (B) hippocampal volume and depressive 
symptoms in patients with Subjective cognitive impairment (SCI) and Alzheimer’s disease 
(AD).   
Figure 9. Associations between medial temporal atrophy and depressive symptoms in 
patients with subjective cognitive impairment (SCI), mild cognitive impairment (MCI) and 
Alzheimer’s disease (AD); data presented as Odds ratios (OR) and 95% CI, MTA: medial 
temporal atrophy  (yes/no), vaMTL: visual assessment of the medial temporal lobe 
(Schelten’s scale); A: Right medial temporal lobe; B: left medial temporal lobe.  
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volume 
5.2 USE OF ANTIDEPRESSANT TREATMENT IN ALZHEIMER’S DISEASE 
AND MORTALITY RISK 
In a large memory clinic cohort of 20,050 patients registered in SveDem with incident 
dementia we found that 25% (n=5,004) were on antidepressant treatment at the time of 
diagnosis. Antidepressants were less commonly prescribed among patients with AD (22.7%) 
and mixed dementia (21.5%), and more commonly in patients with Parkinson Disease 
Dementia (31.7%) and frontotemporal lobe dementia (30.3%). In our study, almost one fourth 
of the patients on antidepressants were prescribed anxiolytic or sedative-hypnotic medication 
at the time of dementia diagnosis and in the three-year period prior to dementia.  
In total 5,168 (25.8%) patients with dementia died during a median follow-up after the 
dementia diagnosis of 2 years (range: 0-5 years).  
We explored the associations between use of antidepressant treatment 3 years prior to a 
dementia diagnosis and mortality risk after diagnosis. Use of antidepressants at any time 
during three-year period in pre-dementia stage was associated with reduced mortality risk 
in the whole cohort (adjusted HR =0.87, 95%CI= 0.80-0.93) and in patients with AD 
(adjusted HR= 0.75, 95%CI= 0.64-0.88). We observed an association between longer 
duration of antidepressant use and lower mortality risk. In the whole cohort we found that 
patients with 2 and 3 years use of antidepressants prior to a diagnosis of dementia had a 
lower mortality risk comparing with non-users of antidepressant treatment (adjusted HR 
and 95%CI for 2 years use were HR:0.83, 95% CI: 0.73-0.93 and for 3 years use were 
HR:0.82, 95%CI: 0.72-0.94) (Table 6). Similarly, we found lower mortality risk (adjusted 
HR 0.61, 95%CI: 0.45-0.83) for using antidepressants 3 consecutive years in prodromal AD 
stage. Use of SSRIs at any time during the three-year interval in pre-dementia stage was 
significantly associated with lower mortality rate in the whole cohort and in patients with 
AD (Table 8). We found no associations between use of antidepressant treatment at the 
time of dementia diagnosis and mortality risk in a median of 2 years follow up. 
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Table 8: Cox proportional hazard models for mortality risk associated with antidepressant use among elderly with dementia 
 Total 
N= 20,050 
AD 
N=7,201 (35.9%) 
MixedD 
N=5,052 (25.2%) 
VaD 
N=3,821 (19.1%) 
Others 
N=3,976 (19.8%) 
Antidepressant use      
 At diagnosis 0.98 (0.92-1.04) 0.98 (0.87-1.11) 1.05 (0.93-1.19) 0.99 (0.87-1.12) 0.95 (0.83-1.10) 
 3 years prior to dementia (yes/no) 
 n=4,325  
0.87 (0.80-0.93) 0.75 (0.64-0.88) 0.94 (0.81-1.10) 0.91 (0.79-1.05) 0.87 (0.74-1.02) 
1 year out of 3 prior to dementia 
n=1814 
0.93 (0.83-1.03) 0.77 (0.62-0.96) 0.97 (0.80-1.20) 1.02 (0.84-1.25) 0.90 (0.72-1.13) 
2 years out of 3 prior to dementia 
n=1383 
0.83 (0.73-0.93) 0.84 (0.66-1.08) 0.78 (0.60-1.01) 0.75 (0.60-0.95) 0.95 (0.72-1.20) 
3 years out of 3 prior to dementia 
n=1128 
0.82 (0.72-0.94) 0.61 (0.45-0.83) 1.10 (0.86-1.41) 0.95 (0.75-1.21) 0.74 (0.57-0.96) 
Antidepressant class- use any of the 3 years prior to dementia 
MAOI 
n=417 
0.87 (0.70-1.07) 0.68 (0.43-1.06) 1.06 (0.73-1.55) 0.77 (0.50-1.20) 0.92 (0.84-1.00) 
SSRI 
n=3261 
0.89 (0.82-0.96) 0.81 (0.68-0.96) 0.92 (0.78-1.08) 0.94 (0.81-1.10) 0.95 (0.77-1.18) 
Other antidepressants  
n=1222 
0.88 (0.78-1.00) 0.73 (0.55-0.96) 0.97 (0.75-1.26) 0.91 (0.71-1.17) 0.97 (0.86-1.09) 
Statistically significant hazard ratios (HR) and 95% confidence interval (95%CI) are shown in bold font (p-value <0.05).  AD, Alzheimer’s disease; 
MixedD, mixed dementia; VaD, vascular dementia; Other includes Parkinson Dementia, dementia with Lewy body; frontotemporal dementia, 
diagnosis of dementia not specified or unknown and any other established diagnosis other than AD, mixed Dementia, VaD, dementia with Lewy body, 
dementia in Parkinson disease.  MAOI, Non-selective monoamine reuptake inhibitors, SSRI Selective serotonin reuptake inhibitors
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5.3 RISK TO DEVELOP DEMENTIA  
5.3.1 CAIDE Dementia Risk Score: mechanisms and progression to dementia  
CAIDE Dementia Risk Score version without APOE genotype was calculated for 724 
patients and 209 (28.9%) had a score indicating higher risk for dementia (8-14 points). 
CAIDE Dementia Risk Score version with APOE genotype was calculated for 310 patients 
and 131 (42.3%) patients had a score indicating higher risk for dementia (9-17 points). The 
baseline demographic data are shown in Table 9. 
Higher scores on CAIDE Dementia Risk Score version without APOE were associated with 
higher CSF t-tau levels (β=0.09, p=0.04), more severe MTA (OR=1.47, 95%CI= 1.01-2.15), 
frontal lobe atrophy (OR= 2.40 95%CI=1.11-5.10) and more severe WMC (OR= 3.41, 
95%CI= 2.20-5.27). Higher scores on CAIDE Dementia Risk Score version with APOE were 
associated with lower CSF-Aβ1-42 (β=-0.27, p= <0.001), more severe MTA (OR=2.71 
95%CI=1.48-5.95) and more severe WMC (OR= 3.91, 95%CI=1.93-7.92) (Table 10). 
324 patients were followed up for 1.36 ± 1.7 years. Progression to dementia occurred in 
23.8% (n=100). 27.6% (n=86) patients with MCI and 3.4% (n=14) patients with SCI 
progressed to dementia. CAIDE Dementia Risk Score version with APOE (AUC 0.64, 
95%CI 0.56-0.73) performed better in predicting dementia than version without APOE  
(AUC 0.58, 95%CI 0.56-0.73) and APOE alone (AUC 0.61, 95%CI 0.53-0.68). CAIDE 
Dementia Risk Score version with APOE had a relatively good sensitivity, but poor 
specificity in predicting dementia (Table 11). 
Table 9. Baseline characteristics of the study sample 
 All (n=724) SCI (N=412) MCI (N=312)  
Age, years* 60.8 (8.5) 58.5 (7.3) 64.0 (8.9) * 
Women, n (%) 417 (57.6) 254 (61.7) 163 (52.2)* 
Education, years* 12.5 (3.7) 13.1 (3.7) 11.8 (3.7) * 
CAIDE Dementia Risk Score 6 (0-14) 6 (0-14) 6.5 (0-14) * 
Hyperlipidaemia, n(%)  201 (27.8) 98 (23.8) 103 (33.0) * 
Hypertension, n(%)  246 (34.0) 111 (26.9) 135 (43.3) * 
BMI, kg/m2* 26.2 (4.1) 26.3 (4.2) 26.1 (4.0) 
MMSE*  27.7 (2.6) 28.3 (2.2) 26.9 (2.9) * 
APOE ε4 carrier, n(%) 156 (21.5) 76 (18.4) 80 (25.6)  
Cornell Depression Scale 6 (0-26) 6 (0-26) 5 (0-24) 
Antidepressant treatment, n (%) 192 (26.5) 114 (27.7) 78 (25.0) 
History of depression, n (%) 261 (36.0) 157 (38.1) 104 (33.3) 
CSF markers    
Aβ1-42, ng/L 855 (56-1920) 910 (286-1920) 718,5 (56-1640) * 
t-tau, ng/L  240.5 (41-1030) 222 (43-689) 273 (41-1030) * 
p-tau181, ng/L  51 (16-183) 49 (16-183) 56 (16-175)  * 
MRI visual ratings n=529   
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MTA   1 (0-4) 1 (0-3) 1 (0-4) * 
GCA-F 0 (0-1) 0 (0-1) 0 (0-1) * 
Parietal atrophy  0 (0-2) 0 (0-1) 0 (0-2) * 
WMC 1 (0-3) 1 (0-3) 1 (0-3) * 
Progression to dementia     
Follow-up, n (%) 324(44.8) 112 (27.2) 222 (71.2) * 
Follow up years mean (SD) 2.90 (1.6) 1.00 (1.5) 2.1 (1.8) * 
Conversion to dementia n (%) 100 (13.8) 14 (3.4) 86 (27.6) * 
Values are medians (range) unless otherwise specified. *Values are means (SD). CAIDE: 
Cardiovascular Risk Factors, Aging and Dementia Study, BMI: body mass index, SCI: 
subjective cognitive impairment, MCI: mild cognitive impairment, MMSE: Mini-mental 
State Examination, APOE: apolipoprotein E genotype, Aβ1-42: amyloid β1-42, t-tau: total tau, 
p-tau181: phosphorylated tau at threonine 181, MTA: medial temporal lobe atrophy (mean 
MTA scores of both hemispheres) , GCA-F : global cortical atrophy frontal subscale, 
parietal atrophy: Koedam score for parietal atrophy, WMC:  white matter changes 
measured with Fazekas scale for white matter changes 
Table 10. Associations of CAIDE Dementia Risk Score with CSF and MRI markers at 
baseline 
 CAIDE risk score (without APOE) CAIDE risk score (with APOE) 
CSF markers, standardized beta-coefficients (p-values) 
Aβ1-42 , ng/L 0-5 points (n=301) Ref 0-6 points (n=81) Ref 
 6-7 points (n=214) -0.04 (0.37) 7-8 points (n=98) -0.22 (0.002) 
 8-14 points (n=209) -0.07 (0.10) 9-17 points (n=131) -0.27 (<0.001) 
t-tau, ng/L 0-5 points (n=301) Ref 0-6 points (n=81) Ref 
 6-7 points (n=214) 0.08 (0.06) 7-8 points (n=98) 0.14 (0.04) 
 8-14 points (n=209) 0.09 (0.04) 9-17 points (n=131) 0.10 (0.17) 
p-tau181, ng/L 0-5 points (n=301) Ref 0-6 points (n=81) Ref 
 6-7 points (n=214) 0.06 (0.17) 7-8 points (n=98) 0.05 (0.49) 
 8-14 points (n=209) 0.05 (0.22) 9-17 points (n=131) 0.05 (0.43) 
MRI visual ratings, OR (95%CI) 
MTA 0-5 points (n=226) Ref 0-6 points (n=57) ref 
 6-7 points (n= 150) 1.11 (0.76-1.62) 7-8 points (n=78) 1.50 (0.80-2.78) 
 8-14 points (n=153) 1.47 (1.01-2.15) 9-17 points (n=100) 2.71 (1.48-5.95) 
WMC 0-5 points (n=226) Ref 0-6 points (n=57) Ref 
 6-7 points (n= 150) 1.80 (1.16-2.77) 7-8 points (n=78) 1.78 (0.87-3.65) 
 8-14 points (n=153) 3.41 (2.20-5.27) 9-17 points (n=100) 3.91 (1.93-7.92) 
GCA-F 0-5 points (n=226) Ref 0-6 points (n=57) Ref 
 6-7 points (n= 150) 1.14 (0.47-2.73) 7-8 points (n=78) 1.48 (0.26-8.40) 
 8-14 points (n=153) 2.40 (1.11-5.10) 9-17 points (n=100) 4.47 (0.99-20.5) 
Parietal atrophy 0-5 points (n=226) Ref 0-6 points (n=57) Ref 
 6-7 points (n= 150) 0.88 (0.52-1.49) 7-8 points (n=78) 0.81 (0.36-1.84) 
 8-14 points (n=153) 1.36 (0.84-2.20) 9-17 points (n=100) 1.46 (0.70-3.05) 
*p<0.05, Standardized beta-coefficients (p-values) are from linear regression with Aβ1-42, t-
tau and p- tau as dependent variable. Odds Ratios and 95% Confidence interval (OR and 
95% CI) are from ordinal logistic regression with MTA, WMC, CGA-F and parietal 
atrophy as dependent variable. CAIDE: Cardiovascular Risk Factors, Aging and Dementia 
Study, Aβ1-42: amyloid β1-42, t-tau: total tau, p-tau181: phosphorylated tau at threonine 181 
MTA: medial temporal lobe atrophy (mean MTA scores of both hemispheres), GCA-F 
global cortical atrophy frontal subscale, parietal atrophy – Koedam score for parietal 
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atrophy, WMC:  white matter changes measured with Fazekas scale for white matter 
changes, APOE: apolipoprotein E genotype 
Table 11. Performance of the CAIDE Dementia Risk Score in predicting dementia 
Cut-off Sensitivity (95%CI) Specificity (95%CI) LR + (95%CI) LR- (95%CI) AUC (95%CI) 
CAIDE Dementia Risk Score (version without APOE) 
6/7 51.0 (40.8-61.1) 60.3 (53.5-66.7) 1.28 (1.00-1.65) 0.81 (0.65-1.02) 0.58 (0.51-0.65) 
7/8 39.0 (29.4-49.3) 72.8 (66.4-78.5) 1.43 (1.03-1.98) 0.84 (0.70-1.00) 
CAIDE Dementia Risk Score (version with APOE) 
7/8 83.6 (71.2-92.2) 42.5 (33.2-51.2) 1.45 (1.19-1.77) 0.39 (0.20-0.73) 0.64 (0.56-0.73) 
8/9 60.0 (45.9-73.0) 61.1 (51.4-70.1) 1.54 (1.12-2.11) 0.66 (0.46-0.93) 
APOE alone 
0/1 69.1 (55.2-80.9) 52.2 (42.6-61.7) 1.45 (1.11-1.88) 0.59 (0.38-0.91) 0.61 (0.53-0.68) 
CAIDE: Cardiovascular Risk Factors, Aging and Dementia Study, LR+: likelihood ratio for 
positive test, LR-: likelihood ratio for negative test, APOE: apolipoprotein E genotype 
5.3.2 Depressive symptoms and risk to develop dementia 
In addition to the published and submitted to publication data, we wanted to use our available 
memory clinic database to explore the association between depressive symptoms and risk to 
develop dementia. Among patients with SCI and MCI, CSDD scores were available for 606 
patients, while information about use of antidepressant treatment was available for all 724.  
At baseline 235 (38.8%) had depressive symptoms (CSDD ≥8) and 192 (26.5%) were on 
antidepressant treatment. The characteristics of the group are shown in Table 12. Patients 
with depressive symptoms at baseline had a lower educational level, and lower MMSE, used 
more antidepressants and more often had a history of depression compared to patients 
without depressive symptoms. Patients using antidepressant treatment at baseline were more 
commonly women, have lower MMSE, more depressive symptoms and a history of 
depression compared to patients without use of antidepressant treatment. After a mean follow 
up time of 2.9 years, 100 (13.8%) patients had developed dementia. Fewer patients with 
depressive symptoms and use of antidepressant treatment at baseline were followed up 
compared to patients without depressive symptoms and use of antidepressants at baseline  
We found that patients with depressive symptoms have a lower risk to develop dementia 
compared to those without (adjusted, HR:0.53, 95%CI: 0.30-0.96), after adjusting for age, 
gender, education, CSF Aβ1-42, t-tau and p-tau181. Similarly depressive symptoms were 
associated with a lower risk to develop AD (adjusted, HR:0.43, 95%CI: 0.20-0.94). No 
significant associations were observed between use of antidepressant treatment and risk to 
develop dementia  (adjusted, HR:1.2, 95%CI: 0.71-1.97).  
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Table 12: Characteristics of the subgroup used for supplementary analysis  
 No Depressive 
symptoms  
N=371 
Depressive 
symptoms 
N=235  
Antidepressants  
Non-users  
N=532 
Antidepressants  
Users  
N=192 
Age men (SD) 62.1 (8.4) 58.7 (8.1) 61.3 (8.4) 59.5(8.5) 
Women # 209 (56.5) 149 (63.4) 293 (55.1) 124 (64.6) * 
Education years men (SD) 12.6 (3.4) 12.2 (4.1)* 12.7 (3.6) 12.0 (4.1) 
Antidepressant treatment # 54 (14.6) 106 (45.1)* - 192  
History of depression # 80 (21.6) 144 (61.3)* 87 (16.4) 174 (90.6)* 
MMSE mean (SD) 28.1 (1.9) 27.03 (3.1)* 28.0 (2.3) 27.0 (3.2)* 
Cornell median (range) 3 (0-7) 12 (8-26)* 5 (0-24) 10 (0-26)* 
SCI # 169 (52.3) 175 (61.8)* 298 (56.0) 114 (59.4) 
MCI # 154 (47.7) 108 (32.8)* 234 (44.0) 78 (40.6) 
Progression to dementia                   N=272                      N=324 
Follow-up, # 191(62.9) 101 (37.1%)* 251 (77.5) 73 (22.5)* 
Follow up years men (SD) 2.8(1.6) 3.1 (1.6) 2.9 (1.6) 2.9 (1.7) 
Conversion to dementia # 68 (35.6) 15 (18.5)* 80 (32%) 20 (27.4) 
*p<0.05, # Values are numbers (percentages) unless otherwise specified. SD: standard deviation, SCI: 
Subjective cognitive impairment, MCI: Mild cognitive impairment, MMSE: Mini Mental State 
Examination  
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6 DISCUSSSION 
6.1 BIOMARKERS OF AMYLOID DEPOSITION AND NEURONAL INJURY IN 
DEPRESSION IN ALZHEIMER’S DISEASE 
We found that AD patients with depressive symptoms had less abnormal biomarkers of 
neuronal injury (lower CSF tau levels and less severe MTA) as compared to AD patients 
without depressive symptoms. SCI patients with depressive symptoms had lower CSF t-tau 
and p-tau181, but more hippocampal atrophy compared to SCI patients without depressive 
symptoms. No significant association was found between the biomarker of amyloid 
deposition (CSF Aβ1-42 levels) and depressive symptoms in SCI or AD. Aβ accumulation 
occurs early in the course of the AD and is considered to be relatively stable at symptomatic 
stages; tau accumulation is more a marker of neuronal injury, which may reflect the 
progressive neurodegeneration and associated cognitive decline 
316
.  
We could not confirm a positive association between biomarkers of amyloid deposition and 
neuronal injury with depressive symptoms. To the contrary, AD patients with depressed 
symptoms seem to have less severe neurodegenerative changes than those without. One 
possible explanation is that AD patients with depressive symptoms seek medical care at 
earlier stages of AD as they have less abnormal biomarkers of neuronal injury. Depression 
and AD are both associated with cognitive impairment. In our study AD patients with and 
without depressive symptoms had a similar overall cognitive performance. AD patients 
without depressive symptoms may have more severe tau and amyloid pathology, since the 
overall cognitive impairment in AD patients with depressive symptoms might be caused by a 
combination of AD pathology and depression associated pathology such as inflammation and 
small vessel pathologies 
139
. Our data did not allow a more detailed cognitive profile, which 
might have informed on this hypothesis.  
On the other hand, another study performed in our memory clinic cohort Lebedeva et al.
204
 
found that depressive symptoms in AD are associated with more severe bilateral superior 
temporal and parietal thinning compared to AD patients without depressive symptoms; but no 
associations were found between hippocampus and depressive symptoms in AD patients. 
Moreover, a significant negative correlation was observed between CSF t-tau levels and 
cortical thickness in the parietal lobe in AD patients with depressive symptoms compare with 
those without
204
. They included a highly selected small cohort of AD patients (n=41) from 
our memory clinic, many of whom had an early onset AD where parietal lobe are known to 
be more atrophic compared to late onset AD
317
. In our study we found a strong association 
between less severe MTA and depressive symptoms in patients with early onset AD, while no 
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such associations were found in late onset AD. One possible explanation may be that in 
patients with early onset AD depressive symptoms do not accelerate the atrophy of the medial 
temporal lobe, but may increase the atrophy of the parietal lobe which is a more specific 
pattern of atrophy in early onset AD. Although depression is a common neuropsychiatric 
symptom in patients with early onset AD, further depression-associated atrophy is not well 
studied
318
.   
In Lebedeva et al. study depressive symptoms had relatively low scores on CSDD (maximum 
CSDD score was 8 points), and in another cohort, the maximum score on GDS 15 was 3 
points. Some of the CSDD and GDS items overlap with apathy and it has been shown that 
apathy is more related to neuronal injury 
201
. Another possible explanation for the apparent 
different findings may be that in our study we defined depressive symptoms using also 
antidepressant treatment, which has been shown to have a protective role for hippocampus
319
. 
Thus, different regimes of antidepressant treatment may have influenced the findings.  
Several definitions for depressive symptoms were used in study II but only depressive 
symptoms defined as “CSDD ≥ 8 or uses of antidepressants” were associated with less 
atrophic MTA. 
In contrast, SCI patients without depressive symptoms had more pathological levels of CSF t-
tau and p-tau181 and less hippocampal atrophy. These patients can be considered elderly 
patients with depressive symptoms and subjective cognitive complaints. Biological processes 
associated with late life depression, such as inflammation and small vessel disease
139
, may 
contribute to the increased hippocampal atrophy
320
. Another possible explanation is that more 
severe hippocampal atrophy in SCI patients with depressive symptoms reflects early 
neurodegenerative changes due to AD in SCI. However, our findings that depressive 
symptoms were not associated with low CSF Aβ1-42 or high CSF t-tau or p-tau181 levels, argue 
against this possible explanation.  
However depressive symptoms co-occur with cognitive impairment and are likely related to 
pathological processes leading to hippocampal atrophy
320
. Depressive symptoms may thus 
represent brain changes that together increase the risk for subsequent development of AD. 
Longitudinal studies are needed to explore the mechanisms underlying this association and 
the observed smaller hippocampi in patients with late life depression
321
. 
6.2  USE OF ANTIDEPRESSANTS IN ALZHEIMER’S DISEASE AND 
MORTALITY RISK  
Depression is often under-diagnosed in older people and antidepressants are the most 
commonly used treatment of depression in patients with and without AD
94
.  
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We found that 25% of dementia patients are on antidepressant treatment at the time of 
dementia diagnosis. Citalopram and mirtazapine were the most frequently prescribed 
antidepressant treatments for the patients with dementia, which were registered in SveDem. 
Our results are similar to a Finnish register-based study where 29% of patients with AD 
used antidepressant treatment and citalopram and mirtazapine were the most commonly 
prescribed drugs
262
. 
To our knowledge, this is the first study exploring the associations between the use of 
antidepressants in pre-dementia stages and mortality risk. The results suggest that use of 
antidepressant treatment in pre-dementia stages reduces mortality in patients with AD. One 
possible explanation is that patients receiving antidepressant treatment for depression or 
another medical condition in pre-dementia stages have a regular contact with a physician 
allowing an earlier diagnosis of dementia; implying a better treatment and care for dementia 
and other diseases which may reduce mortality. A higher mortality rate is associated with a 
late diagnosis of AD on the trajectory of the disease
322
. The results support the findings from 
Study I and II which suggest that patients with AD and depression are in earlier stages of AD 
at the time of diagnosis and therefore may have lower mortality rate.  
Behavioural symptoms are associated with increased mortality risk in patients with dementia 
102
. Another possible explanation is that antidepressant treatment may be useful in treating 
these symptoms including depression in AD and dementia
323
 and therefore decreases 
mortality rate
109
.  
Antidepressants may have biological effects, which lead to reduced mortality in patients with 
AD. We found an association between longer duration of antidepressant treatment and lower 
mortality risk. Some studies have found that use of antidepressants like citalopram reduces 
Aβ production247 and that use of antidepressants can delay onset of dementia and increase 
longevity in patients with Down syndrome
248
. Meanwhile other studies reported that 
antidepressants are associated with hippocampal atrophy
246
 and increased risk for 
dementia
249
.  
Antidepressants have been previously found to reduce mortality risk in the elderly with late 
life depression
123
. Most of the studies conducted in nursing homes on individuals with 
different degrees of cognitive impairment found an association between use of 
antidepressants and reduced mortality risk
108,109
. Additionally one study from nursing homes 
found that use of antidepressant treatment more than one year is associated with lower 
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mortality risk
108
. In contrast, a study that included outpatients found a small but significant 
increased in mortality risk in patients with AD on antidepressants
95
.  
6.3 RISK TO DEVELOP DEMENTIA 
6.3.1 CAIDE Dementia Risk Score: mechanisms and progression to dementia  
We found that CAIDE Dementia Risk Score was associated with biomarkers of amyloid 
deposition, neuronal injury and small vessel pathology, and a higher risk of progression to 
dementia. 
Several risk scores for dementia have been developed taking into account modifiable vascular 
and lifestyle-related risk factors
21,324–327
 .CAIDE Dementia Risk Score is one of the scores 
developed in the general population with a high potential to be used in clinical practice in 
dementia risk assessment
21
. The risk of cognitive disorders increases with age
149
. Risk scores 
like CAIDE Dementia Risk Score can select individuals at risk to develop dementia and who 
can benefit from lifestyle interventions
91
. Currently, there are no pharmacological therapies 
approved for patients with subjective or mild cognitive impairment. 
This is the first study that assesses the associations between CAIDE Dementia Risk Score and 
biomarkers of amyloid deposition, neuronal injury and small vessel disease, as well as the 
score performance to predict dementia in patients with SCI and MCI from a memory clinic. 
These findings thus support the validity of the score and its clinical relevance. Aβ and tau 
pathologies often coexist and interact with cerebrovascular pathology, particularly small 
vessel disease 
86,328
. CSF t-tau and p-tau181, and MTA on MRI are considered to reflect the 
burden of neurofibrillary tangles 
72
, while WMC are found in AD
86
, and potentiate the effects 
of cortical atrophy on cognitive impairment 
329
. 
The association between CAIDE Dementia Risk Score and WMC is expected as the score is 
mainly based on cerebrovascular risk factors
21
, and the risk factors included in the score such 
as midlife hypertension
330
, hypercholesterolemia
331
 and obesity
332
 have already been 
associated with pathological biomarkers for neuronal injury or amyloid deposition. 
Our results support previous reports from a population-based study where CAIDE Dementia 
Risk Score was associated with more severe hippocampal atrophy and WMC up to 30 years 
later
333
. In addition to their findings, we found that the score correlates with CSF t- tau levels.  
A memory clinic sample is a selected cohort at risk to develop dementia, thus high numbers 
of APOE ε4 carriers (50.3%) is expected. We found that higher CAIDE Dementia Risk Score 
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including APOE was associated with reduced CSF Aβ1-42 levels, suggesting accumulation of 
Aβ in the brain.  
In the original publication, including APOE genotype in CAIDE Dementia Risk Score did 
not improve the score’s capacity to predict dementia 20 years later in the general 
population
21
. However, adding APOE genotype to CAIDE Dementia Risk Score improved 
the score’s capacity to predict dementia a few years later in memory clinic patients already at 
risk to develop dementia. CAIDE Dementia Risk Score version with APOE has a good 
sensitivity, but low specificity at a cut-off ≥ 8. The risk score may thus be useful for 
identifying individuals at risk to develop dementia and who could therefore benefit more 
from lifestyle interventions and vascular and metabolic risk management 
91
.  
6.3.2 Depressive symptoms and risk to develop dementia  
In our memory clinic database, we found that SCI and MCI patients with depressive 
symptoms have a lower risk to develop dementia during a short follow up period. We found 
no associations between antidepressant treatment and risk to develop dementia. There is a lot 
of evidence from community based studies that depression is a risk factor for dementia and 
predicts conversion from MCI to dementia
147
. The evidence is inconsistent in clinical studies 
as a large amount of clinical based studies could not confirm the associations found in 
epidemiological studies
147
.  Our results are similar with the results from a memory clinic 
study that reported MCI patients with depressive symptoms have a lower likelihood to 
convert to dementia after 2 years of follow up
278
. Our findings support the results reported in 
study I and II, that suggest that patients with depressive symptoms seek medical help in 
earlier stages of the disease. Depressive symptoms can lead to memory complains and 
personality changes that are observed in early stages of MCI and dementia
50
. However, fewer 
patients with depressive symptoms or using antidepressants were followed up, and this may 
have influenced the findings. 
6.4 METHODOLOGICAL LIMITATIONS 
The present studies have a number of methodological limitations. All studies used a 
retrospective design, using already collected data. Studies I, II, IV have a cross-sectional 
design and thus assumptions regarding causality cannot be made. Studies III and IV used a 
retrospective design, but included longitudinal data of progression to dementia, drug use and 
survival. Only patients referred to memory clinics were included and thus generalisations to 
the population are not possible. The naturalistic design inevitable leads to some missing data.  
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The cohorts for studies I, II and IV included patients from one university memory clinic and 
no inter-rater reliability studies are available. Although regular attempts are made to enhance 
standardization and harmonization of the procedures, no formal reliability studies of the 
diagnostic procedures and clinical rating scales have been performed. However, the use of 
standardized procedures, validated clinical rating scales including neuropsychological testing, 
extensive biomarker assessment, longitudinal follow-up of many patients, and a final 
diagnosis based on a consensus meeting suggest that the diagnoses are accurate. However, 
since there was no autopsy confirmation the diagnostic accuracy is not known.  
Patients with SCI and MCI have and increased risk to develop dementia and as a group have 
more advanced stage of Aβ pathology, neuronal injuries, or small vessel pathology, and an 
increased prevalence of the APOE ε4 allele compared to the general population334. For the 
first two studies the comparison group consisted of patients with SCI, with a high risk of 
developing AD and increased proportion of pathological CSF and MRI findings
334
 . Thus, 
this is not a “healthy” control group and thus extrapolation to elderly without AD suffering 
from depression cannot be made. 
In study III patients were included from several memory clinics across Sweden using 
different assessment protocols and neuropsychological test batteries. The data obtained did 
not contain information on cognitive performance in preclinical stages of dementia and 
patients with SCI and MCI are not included in SveDem. The accuracy of diagnoses of 
dementia in SveDem are not validated independently with autopsy records. Patients suffering 
from dementia with Lewy bodies, Parkinson’s disease dementia and vascular dementia may 
not be representative for the population of these diagnoses since a large proportion are likely 
to be seen by neurologist or other clinics and only a selection of those with early, severe, or 
atypical cognitive impairment may be referred to memory clinics and registered in SveDem 
335
. However, experienced specialists using clinical information and several biomarkers in 
order to increase the diagnostic accuracy established the diagnoses. Detailed analyses have 
shown that in SveDem less than 5% of the diagnoses are changed after the yearly follow-
up
101
. 
Another limitation is that patients were considered to have depressive symptoms based on 
CSDD scores and not on a structured diagnosis interview. Trained nurses and clinicians were 
applying the scale but no data on intra- and inter-rater reliability were available. Moreover, 
the Swedish version of the scale used for this study is not validated in a Swedish population, 
most of the validation studies were in culturally similar populations from Norway
220
 and 
Denmark
218
. However, the CSDD is the recommended tool for assessing depressive 
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symptoms in people with cognitive impairment
238
, and has been shown good psychometric 
properties
220
.  Throughout the thesis we used several cut-off points on CSDD to define 
depressive symptoms.  We used 2 cut-off points, which are validated in a Danish (6/7)
218
, and 
a  Norwegian (7/8) cohort of out patients
220
. In study II we defined depressive symptoms as a 
CSDD score more and equal 8 or use of antidepressant treatment
140
, as it have been suggested 
that information on use of antidepressant treatment can improve the classification 
accuracy
140
.  
The patients were referred for memory rather than mood problems, and thus the depressive 
symptoms were usually of mild and sometimes moderate severity. Thus, although our 
findings are relevant for memory clinic cohorts, they may not be valid for patients with 
dementia and clinically significant depression. Data on clinical features such as history of 
depression (age at onset, number and severity of episodes) and on duration and indication 
of antidepressant treatment were not available.  
In study III we used data on antidepressant treatment from the Swedish Prescribing Drug 
Register, which covers dispensation of all dugs in all Swedish pharmacies, but does not 
contain information on prescriptions during hospitalization, indication of, or adherence to 
treatment. 
In study II we assessed the medial temporal lobe structures using two methods well correlated 
with each other 
303
: visual assessment of the medial temporal lobe and manual delineation of 
the hippocampal volume. Differences between these 2 methods can explain the different 
results in patients with SCI and AD. The visual assessment is an approximate measure of the 
medial temporal lobe, which includes other brain structures such as the entorhinal cortex that 
is affected in both late life depression 
336
 and AD 
27
. We limited our research to medial lobe 
structures, although there are other brain changes such as atrophy of frontal lobe
337
 and more 
severe white matter changes
338
, which might have influenced the findings.  
The visual assessment was performed on T1 weighted MRI images with different protocols 
of acquisition, and in study II we used both CT and T1 weighted MRI scans. However, a 
good intra-observer agreement had been shown between multi-detector row CT and 1.5 Tesla 
MRI for vaMTL on the left and right hemisphere
302
 
Another methodological limitation of study II is that the results were not corrected for 
multiple statistical comparisons.  Thus, there is a risk for false-positive findings. 
In study IV CAIDE Dementia Risk Score was not calculated according to the original version 
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as data on physical activity were not available
21
. However, we used the same version of 
CAIDE Dementia Risk Score used in the validation study, which did not include physical 
activity
25
. Furthermore, follow up data are available only for patients considered with a high 
risk to develop dementia at baseline. Additional analyses were conducted to address the 
missing data (see statistics study IV).  However, in a small intern study 30 randomly selected 
patients with SCI without follow up were invited to a new neurocognitive assessment after 5 
years, and none of them developed dementia in this period
339
.  
7 CONCLUDING REMARKS AND FUTURE PERSPECTIVES  
7.1  GENERAL CONCLUSIONS  
Our findings do not support the hypothesis that depressive symptoms are associated with 
more severe amyloid deposition and neuronal injury in patients with AD. Antidepressants are 
used by a quarter of newly diagnosed patients with dementia at the time of diagnosis. Use of 
antidepressant treatment in prodromal stages of AD is associated with lower mortality risk.  
In a memory clinic cohort, CAIDE Dementia Risk Score was associated with biomarkers of 
amyloid deposition, neuronal injury, and can predict development of dementia. 
7.2 SPECIFIC CONCLUSIONS  
 Patients with AD and depressive symptoms have lower pathological levels of the CSF 
t-tau and less atrophy of the medial temporal lobe than AD patients without 
depressive symptoms. 
 Patients with SCI and depressive symptoms have less pathological CSF t-tau and p-
tau181, but more severe hippocampal atrophy compared to SCI patients without 
depressive symptoms 
 25% of patients newly diagnosed with dementia use antidepressant treatment at the 
time of diagnosis. 
 Citalopram and mirtazapine are the most commonly used antidepressants at the time 
of dementia diagnosis 
 Use of antidepressant treatment for 3 consecutive years in prodromal stages of AD is 
associated with a lower mortality rate after AD diagnosis 
 In a memory clinic cohort of patients with SCI and MCI, higher CAIDE Dementia 
Risk Score version with APOE genotype is associated with biomarkers of amyloid 
deposition, neuronal injury and small vessel pathology.  
 In a memory clinic cohort of patients with SCI and MCI, CAIDE Dementia Risk 
Score version with APOE genotype predicts better dementia up to 7 years later.  
  75 
 In a memory clinic cohort of CAIDE Dementia Risk Score has a low specificity, but a 
good sensitivity to predict dementia in 2.9 year follow up period.  
7.3 FUTURE DIRECTIONS  
In order to understand the mechanisms implicated in depression in AD further longitudinal 
studies are necessary. This may help clarify the relationship between depressive symptoms, 
psychological factors and biomarkers of amyloid deposition, neuronal injury, small vessel 
disease, neuroinflammation as well. Future studies will benefit from the use of recently 
proposed research criteria for subjective cognitive decline
49
 which were not available when 
the thesis was planned.   
Our findings that antidepressants can reduce mortality in AD needs to be replicated in a 
prospective study. More evidence is needed to understand the mechanisms underlying 
antidepressants’ effect on mortality in AD and other dementia disorders. A key future 
question is to explore whether use of antidepressants can reduce the risk for developing AD 
or can delay onset of AD. Further studies need to address the safety of specific 
antidepressants in prodromal stages of AD. Finally, since available antidepressants do not 
seem to be effective in people with AD, it will be important to develop novel treatments. 
A further research question is, can CAIDE Dementia Risk Score predict brain pathology 
and what type of pathology? Future studies should be prospective and formulate an adapted 
version of CAIDE Dementia Risk Score for use in memory clinic patients with SCI and 
MCI. Behavioural symptoms and other biomarkers can be included to improve the score’s 
performance in a memory clinic cohort with a high risk to develop dementia.  
Our studies have several implications for clinical practice. We have confirmed other 
findings that depressive symptoms and use of antidepressants are common among memory 
clinic patients. Accordingly, in memory clinics screening for depressive symptoms and a 
critical review of psychopharmacological treatment is important. Effective multimodal 
management strategies are needed. Our findings that antidepressants do not increase 
mortality in patients with early AD, and might even reduce mortality, are re-assuring, and 
suggest that antidepressants are safe in these patients. CAIDE Dementia Risk Score can aid 
in the dementia risk assessment of patients with SCI and MCI, which may be particularly 
useful in centres with less resources for more sophisticated biomarker analyses. The score 
may also be used to recruit patients who can benefit from life style or other management 
interventions as well as for inclusion in clinical trials.  
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Annex: CAIDE Dementia Risk Score version used in study IV. 
CAIDE Dementia Risk Score  
  
 Version without  
APOE genotype 
Version with  
APOE genotype 
Age, years  <47  
 47-53        
 >53  
            0 
            3 
            4 
        0 
        3  
        5 
Education, years  ≥10  
 7-9  
 0-6  
            0 
            2 
            3 
        0 
        3 
        4 
Sex  Women 
 Men 
            0 
            1 
        0 
        1 
Hypertension  No 
 Yes 
            0 
            2 
        0 
        2 
BMI, kg/m
2
  ≤30 
 >30 
            0 
            2 
        0 
        2 
Hyperlipidemia No 
Yes 
            0 
            2 
        0 
        1 
APOE ε4   Non-carrier 
 Carrier 
            - 
            - 
        0 
        2 
Total points     Max 14 p      Max 17 p 
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